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1. Introduction 
1.1. The medical plant milk thistle (Silybum marianum (L.) Gaertn.) 
Milk thistle belongs to the family Asteraceae, genus Silybum and species Silybum 
marianum. According to an ancient legend the virgin Mary lost some drops of milk during 
breast feeding of her new-born child which caused the white spots on the white-veined 
leaves of the plant (Siegel and Stebbing, 2013) (figure 1.1). Milk thistle is grown in the 
Mediterranean region as a native home, but is cultivated in Asia and Europe for centuries. 
The active compound is called silymarin and is composed of seven flavonolignans 
(Silibinin (Silybin) A, Silibinin (Silybin) B, Isosilybin A, Isosilybin B, Silychristin, 
Isosilychristin and Silydianin) and one flavonoid (Taxifolin). Silymarin represents about 
65%-80% of milk thistle extracts. Flavonoids are natural occurring substances that have a 
polyphenolic structure. They belong to secondary metabolites and are found in fruits, 
vegetables, grains, bark, flowers, roots, stems, tea and wine. Flavonoids are responsible for 
the pigment of flowers and exert anti-oxidative and anti-inflammatory properties (Panche et 
al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Silibinin (A) Milk thistle flower (http:/doctormurray.com/the-positive-
estrogenic-effect-of milk-thistle-extract). (B) Milk thistle seeds 
(https://www.saltspringseeds.com/products/milk-thistle-silybum-marianum-1). (C) Leaves 
of milk thistle. 
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Silymarin has been utilized for more than 2000 years as a general medical herb. Since the 
sixteenth century, it is used for hepatoprotection in humans, because of its strong anti-
hepatotoxic activity against different types of liver damage and toxicity (Dehmlow et al., 
1996; Schuppan et al., 1999; Wellington and Jarvis, 2001; Polyak et al., 2013). In the early 
1990s, various reports described the use of milk thistle as a potential chemopreventive 
agent against cancer diseases (Kroll et al., 2007; Gufford et al., 2015). Furthermore, Silybin 
appears an encouraging medication for chronic liver disease due to hepatitis C virus (HCV) 
infection (Loguercio and Festi, 2011). 
1.2. Silibinin 
Silibinin is the major active compound of Silymarin, comprising 50-70% of it. Silibinin is 
largely water-insoluble, and it is slowly absorbed in the intestine, needing about 3-6 hours 
to be completely absorbed. To increase resorption and bioavailability, a water soluble 
derivative of Silibinin, i.e. a mixture of Silibinin A and B dihydrogen disodium succinate, 
which is sold under the trade name Legalon® SIL, was synthetised (Mengs et al., 2012) 
(figure 1.2). 
In Germany, Legalon Sil is used intravenously for the treatment of toxic mushroom 
poisoning. In addition, Silibinin was demonstrated to exert considerable anti-viral action 
against HCV (Ferenci et al., 2008; Wagoner et al., 2011; DebRoy et al., 2016). 
 
 
 
 
 
  
 
 
 
 
 Figure 1.2: Legalon® SIL for intravenous treatment. 
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1.3. Differences between Silibinin and Legalon SIL 
1.3.1. Chemical structure  
Silibinin, consists of a 1:1 mixture of two diastereoisomers, Silibinin A and Silibinin B. 
Moreover, Silibinin was presented as isosilybin, consisting of isosilybin A and isosilybin B, 
as ratio 1:1 mixture of two diastereoisomeric compounds (Lee et al., 2007; Loguercio and 
Festi, 2011; Samanta et al., 2016). Legalon SIL consists of a 1:1 mixture of disodium 
disuccinyl Silibinin A and disodium disuccinyl Silibinin B. Silibinin is dissolved in 
dimethylsulfoxide (DMSO), while Silibinin-C-2’,3-dihydrogen succinate, disodium salt 
(Legalon SIL), which has been developed by Dr. Ulrich Mengs and Ralf T. Pohl 
(Rottapharm/Madaus), is dissolved in water (Wagoner et al., 2011; Mengs et al., 2012) 
(figure 1.3). 
 
 
1.4. Biological activity of Silibinin 
Silibinin is the main active biological ingredient of the milk thistle, it has several biological 
activities. It is anti-inflammatory, anti-oxidant, anti-proliferative, anti-fibrotic, anti-
neoplastic, immunomodulatory and anti-viral (Agarwal et al., 2006; Polyak et al., 2007; 
Polyak et al., 2010; DebRoy et al., 2016).  
 
 
 
Figure 1.3: Chemical structures of Silibinin (A) Silibinin-C-2’, 3-dihydrogen succinate, 
disodium salt. (Legalon SIL) (Mengs et al., 2012), (B) Silibinin (Wu et al., 2008).  
-A- -B-
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1.5. Medical benefit of Silibinin 
Currently Silibinin it is applied as hepatoprotective as well as anti-viral agent against HCV 
in humans (Polyak et al., 2013). It exerts proven anti-hepatotoxic activity against different 
types of liver damage and toxicity (Dehmlow et al., 1996; Wellington and Jarvis, 2001; 
Payer et al., 2010; Federico et al., 2017). 
Many studies confirmed the benefits of Silibinin and Legalon SIL in the treatment of liver 
disorders such as hepatitis and alcoholic liver cirrhosis as well as mushroom poisoning with 
Amanita phalloides toxin (Varghese et al., 2005; Cheung et al., 2010; Mengs et al., 2012).  
In addition to its hepatoprotective effects, Silibinin has recently been shown to possess 
bone-forming and osteoprotective effects in vitro (Kim et al., 2012; Kim et al., 2013). 
Moreover, it has been suggested to act as an inhibitor of A amyloid aggregation, thus 
reducing memory impairment in vivo. Therefore Silibinin may be a potential therapeutic 
agent for the treatment of Alzheimer’s disease (Yin et al., 2011; Tota et al., 2011). 
Furthermore, Silibinin has anti-hyperglycemic properties, due to its capacitiy to enhance 
the glycemic control in Type 2 diabetic mellitus patients (Lirussi et al., 2002; Voroneanu et 
al., 2016). Not least, Silibinin has cosmeceutical properties and has been shown to support 
effective wound healing (Singh and Agarwal, 2009; Samanta et al., 2016). 
 
1.6. Anti-cancer activity of Silibinin 
Silibinin was applied as a chemopreventive agent in a variety of in vitro and in vivo cancer 
models of epithelial cancer such as skin cancer (Cheung et al., 2010; Singh et al., 2014), 
lung cancer (Singh et al., 2006; Mateen et al., 2013), bladder cancer (Tyagi et al., 2004; 
Singh et al., 2008; Zeng et al., 2011), as well as cancers of colon, breast, prostate and 
kidney (Cheung et al., 2010; Özten-Kandaş and Bosland, 2011; Kim et al., 2011; Zheng et 
al., 2017).  
 
1.7. Action of Silibinin as an antagonist of angiotensin II (Ang II) signaling  
Research on the Renin-Angiotensin System (RAS) has revealed the primordial impact of 
Ang II in cardiovascular diseases and blood pressure control (Benigni et al., 2010). In the 
heart, the pharmacological activity of Silibinin is so far not investigated. Recently it was 
suggested that Silibinin may act as an antagonist of the angiotensin receptor 1 (AT1) since 
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Silibinin abolished Ang II-mediated Ca
2+
 signals in Chinese hamster ovary (CHO) cells 
over-expressing the AT1 receptor (Bahem et al., 2015). Cardiomyocytes express the AT1 
as well as the AT2 receptor (Busche et al., 2000). In the cardiac conduction system 
increased Ang II may induce cardiomyocyte apoptosis (Vongvatcharanon et al., 2004). It 
has role in cardiac hypertrophy (Zhu et al., 2003; Chen et al., 2017), depending on the 
experimental conditions and the expression pattern of AT receptor subtypes. In ES cells 
Ang II has been shown to regulate glucose uptake (Han et al., 2005), supporting the notion 
that Ang II may play a role in the energy metabolism during embryogenesis. Notably Ang 
II has been demonstrated to stimulate cardiomyogenesis of ES cells (Wu et al., 2013). In 
differentiating ES cell-derived EBs the AT1 receptor is expressed already at very early 
stages of cardiac cell commitment. Components of the RAS are highly expressed in many 
tissues during embryonic development. AT1 receptor expression is downregulated shortly 
after birth, whereas the AT2 receptor is upregulated, suggesting a potential role of AT1 in 
cell/tissue differentiation processes during embryogenesis and AT2 in adult organ function 
(Gao et al., 2012). In fetal ovine cardiomyocytes Ang II stimulates hyperplastic growth 
(Sundgren et al., 2003), indicating that Ang II is involved in fetal heart growth. Moreover, 
besides insulin-like growth factor (IGF) receptors, AT1 receptor expression has been 
shown to be present in human cardiac stem cells (D'Amario et al., 2011), thus outlining an 
impact of Ang II signaling in cardiac progenitor cell differentiation and/or proliferation. 
 
1.8. Stem cells 
Stem cells are undifferentiated cells which can develop to different cell types of all tissues 
of the body. They can originate from the embryo, fetus and grown-up to adult (Passier and 
Mummery, 2003; Li and Ikehara, 2013). One of most important features of stem cells is 
their self-renewing capacity. This implies that following the division of a mother cell, one 
daughter cell remains a stem cell, thus sustaining the stem cell pool, whereas the other 
daughter cell is entering differentiation pathways to give rise to multiple types of cells and 
tissues (Bjornson et al., 1999; Toma et al., 2001). The self-renewing capacity of stem cells 
implies that they can be kept under appropriate conditions in culture for prolonged times 
and cell division cycles. Notably, stem cells retain their karyotype even after multiple 
passages in cell culture (Bradley et al., 1984; Vats et al., 2005; Jin et al., 2016). According 
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to the differentiation potency of stem cells they are classified as: totipotent, pluripotent, 
multipotent/oligopotent and unipotent (figure 1.4). 
 
Totipotent stem cells 
Totipotent stem cells are cells with the capacity to form an entire, independent organism. In 
mammalian organisms, embryonic cells are considered totipotent until the 8-16 cell stage of 
embryonic development (Johnson and Ziomek, 1981; Marikawa and Alarcón, 2009; 
Gonzalez et al., 2016). 
 
Pluripotent stem cells 
Pluripotent stem cells derive from totipotent stem cells and have the capacity of self-
renewal and differentiation into all cell types within the organism. Pluripotent stem cells 
comprise of ES cells, embryonic germ (EG) cells and embryonic carcinoma (EC) cells 
(Beddington and Robertson, 1989; Boheler et al., 2002; Lensch et al., 2006). 
 
Multipotent/oligopotent stem cells 
Multipotent stem cells possess the ability to differentiate into all cell types within one 
specific lineage. Since multipotent stem cells are present in adult organisms, they may play 
important roles in tissue repair and protection. Moreover, they can be used in cell therapies 
of, e.g. spinal cord injury, bone fractures, autoimmune diseases, rheumatoid joint 
inflammation, hematopoietic defects, and fertility preservation (Sobhani et al., 2017). 
 
Unipotent stem cells 
Unipotent cells have a very limited differentiation potential and differentiate just into one 
cell type. Examples are: satellite cells of skeletal muscle or hematopoietic progenitor cells 
which give rise to only one specific type of blood cells (e.g. erythroblasts) (Dulak et al., 
2015). 
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1.9. Embryonic stem (ES) cells 
ES cells are derived from the inner cell mass of blastocysts. Their stemness is regulated by 
stemness genes which express the core pluripotency factors: Nanog, Oct4, Sox2, and other 
factors: Klf2, Klf4, Tfcp2l1, Esrrb, Gbx2, and Sall4 (Bourillot et al., 2009; Aksoy et al., 
2014; Qiu et al., 2015). The signal transduction pathways elicited by LIF, bone 
morphogenetic protein (BMP) and Wnt support self-renewal and pluripotency of ES cells 
through upregulation of the transcription factor Nanog. Furthermore, intrinsic transcription 
factors such as FoxD3, P53 and Oct4 have a role in regulating Nanog expression to 
maintain mouse ES cell properties (Pan and Thomson, 2007). 
Figure 1.4: Extraction and culture of ES cells.  
 
Totipotent
Pluripotent
Multipotent
Zygote 
Fertilized egg
Morula
Blastocyst stage
Fetus
Culture undifferentiated stem cells
Blood cells
Cardiac muscle
Neural Cells
Inner cell mass
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Mouse ES cells were isolated and grown in vitro for more than 20 years (Martin, 1981; 
Evans and Kaufman, 1981). The pluripotency of mouse ES cells can be maintained if the 
culture contains the cytokine LIF. Upon removal of LIF, mouse ES cells are going to 
differentiate spontaneously to form EBs in vitro (Stewart et al., 1992; Burdon et al., 2002; 
Wobus and Boheler, 2005). LIF is a member of the interleukin-6 (IL-6) family of cytokines 
and promotes self-renewal by activating janus kinase/signal transducers and activator of 
transcriptions (JAK/STAT), mitogen activated protein kinase (MAPK) and PI3K signaling 
cascades (Nicola and Babon, 2015).  
Human ES cell (hESC) lines were firstly derived from human embryos in 1998 by 
Thomson et al., 1998, and have since then been proven as un-restricted source of cells for 
regenerative medicine (Wobus and Boheler, 2005). hESCs were derived from blastocysts 
obtained after in vitro fertilization (Pera et al., 2000). hESCs share basic qualities with 
mouse ES cells, such as the maintenance of stemness by the transcription factors Oct-4, 
Sox-2 and Nanog as well as the capacity to form three germ layers (ectoderm, endoderm 
and mesoderm) (Richards et al., 2002; Boyer et al., 2005). However, in hESCs, LIF is 
imperfect to suppress the differentiation process (Pera et al., 2000). 
 
1.10. Cardiomyogenesis  
Cardiomyogenesis is defined as the differentiation of pluripotent stem cells to specialized 
cell types of the heart, such as atrial-like, ventricular-like and sinus nodal–like cells. During 
the differentiation process, cardiac-specific genes, receptors, ion channels and proteins are 
expressed (Wobus, 2001; Boheler et al., 2002). In early stages of differentiation, 
cardiomyocytes inside EBs are small and round with single nuclei. The early myofibrils are 
sparse and irregularly organized, while others contain parallel bands of myofibrils that 
show A and I bands. However, with maturation, these cells are going to be distinctly 
lengthened and develop regular myofibrils and sarcomeres. Beating cells are principally 
mononucleated, rod-shaped and they contain cell-cell junctions with developing cells in the 
heart (Westfall et al., 1997; Tajsharghi, 2008). 
There are several of transcription factors which have important roles in cardiomyocyte 
differentiation, such as Nkx2.5, GATA and MEF2. Nkx2.5 is required for heart 
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development, and is regulating the expression of myocardin which is important for 
cardiomyogenesis (Jamali et al., 2001; Ueyama et al., 2003). 
Sarcomeric proteins of cardiomyocytes are established in the following order: titin (Z disk), 
myomesin, α-actinin, titin (M band), myosin heavy chain (MHC), α-actin, cardiac troponin 
T and M protein (Skwarek-Maruszewska et al., 2013; White et al., 2014). The GATA 
family of transcription factors plays a role in cardiac development that leads to heart muscle 
differentiation (Brewer and Pizzey, 2006). Studies of cis-regulatory elements have 
confirmed the important role of GATA factors (particularly GATA-4) in promoting the 
expression of many myocardial genes, including α- and β-myosin heavy chain (α- and β-
MHC) and cardiac troponin C (Zeisberg et al., 2005; Hewitt et al., 2016). 
 
1.11. Calcium (Ca
2+
) signaling 
The Ca
2+
 ion is the main ion in cell signaling. Ca
2+
 has regulatory functions in gene 
transcription, cell motility and exocytosis (Bonny and Bochud, 2014). In addition, Ca
2+ 
is 
an important secondary messenger in cell signaling and regulates physiological functions 
including contraction of cardiac-, smooth- and- skeletal muscle and release of hormones 
and neurotransmitters. Moreover, Ca
2+
 drives stem cells towards cardiac cell differentiation 
through regulation of cardiac transcriptional cascades, secretion of cardiogenic factors and 
in turn gene expression and myofibrillogenesis (Pucéat and Jaconi, 2005). Dysregulation of 
intracellular Ca
2+
 can lead to loss of physiological function and pathological changes in cell 
growth (Zhang et al., 2004).  
In mature cardiomyocytes Ca
2+
 sparks occur which are activated by voltage-dependent L-
type Ca
2+ 
channel (LTCC) mediated Ca
2+
 influx. Ca
2+
 sparks are the basic unit of heart 
excitation-contraction (E-C) coupling in the adult. Ca
2+
 sparks occur during E-C coupling 
when Ca
2+ 
enters the cells through LTCCs and activates the ryanodine receptor (RyR) on 
the sarcoplasmic reticulum (SR) to release Ca
2+
 from intracellular stores. This process is 
named Ca
2+ 
-induced Ca
2+ 
release (CICR) (Zhang et al., 2004; Pucéat and Jaconi, 2005). E-
C coupling is ended by removal of intracellular Ca
2+
 from the cytoplasm which is 
accomplished by the sarcoplasmic reticulum (SR) Ca
2+ 
ATPase (SERCA) and 
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Figure 1.5: Schematic figure explaining Ca
2+
 regulation in cardiac cells. Influx of Ca
2+ 
through LTCCs releases Ca
2+ 
through RyRs. Ca
2+ 
is pumped back into the SR through 
SERCA which is controlled by PLB. In addition, the Na
+
/ Ca
2+ 
exchanger (NCX) removes 
Ca
2+
 from the intracellular compartment. ~p = phosphorylation. 
 
. 
 
phospholamban (PLB). In the heart the SERCA isoform SERCA2a is expressed. The 
activity of SERCA2a is controlled by the phosphorylation state of PLB (figure 1.5).  
 
 
 
 
 
 
 
 
 
    
 
1.12. Vasculogenesis from ES cells 
During embryonic development a vascular network is formed to provide the growing 
embryo with oxygen and nutrients. The process of blood vessel formation can be divided in 
two processes, namely vasculogenesis and angiogenesis (Geudens and Gerhardt, 2011). 
The initial process of blood vessel formation from vascular progenitor cells is termed 
vasculogenesis (Geudens and Gerhardt, 2011; Rakocevic et al., 2017). It happens when 
angioblasts, i.e. vascular endothelial cell precursors (precursor cells) are differentiated, 
expand and adhere to form endothelial cells which multiply inside a former vascular tissue 
to generate a primitive capillary plexus (Risau and Flamme, 1995). The different steps of 
vasculogenesis from ES cells can be monitored by immunohistochemical analysis of 
PECAM-1 - positive areas in EBs (Bekhite et al., 2016). PECAM-1 (or CD31) is expressed 
RyR 
 
LTCC 
Ca
2+ 
SR 
Ca
2+ 
~p 
Ca
2+ 
SERCA PLB 
~p 
~p 
NCX ~p 
Ca
2+ 
3Na
+ 
T-tube 
~p 
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in the cell junctions between endothelial cells and plays important roles in cell adhesion 
and signal transduction (Newman et al., 1990; Müller et al., 2002). 
Outgrowing blood vessels contain two different types of cells: tip cells and vessel elements. 
Tip cells migrate depending on the mechanical forces induced by neighboring vessel 
elements and the local tissue (Perfahl et al., 2017). During angiogenesis, new blood vessels 
arise from pre-existing vessels (figure 1.6). These vessels can be formed by two 
mechanisms: sprouting angiogenesis and intussusception.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood vessels may originate from endothelial cells, while tissue columns are embedded 
inside existing vessels to split the vessels. As a result, the development of these segments 
and their adjustment leads to division of the vessel and remodeling of the neighboring cells 
Figure 1.6: Schematic representation of vasculogenesis and angiogenesis (Korpisalo 
and Ylä-Herttuala, 2010). 
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of blood vessels (Risau, 1997; Patel-Hett and D’ Amore, 2011). Vasculogenesis and 
angiogenesis are regulated by hypoxia through hypoxia inducible factor-1α (HIF-1α) which 
regulates the expression of vascular endothelial growth factor (VEGF) (Sauer et al., 2001a). 
1.13. Factors involved in vasculogenesis and angiogenesis 
VEGF is the essential angiogenic growth factor that modifies angiogenesis through 
receptor tyrosine kinase VEGF receptors (VEGFRs). The VEGF family comprises of 
various members: VEGF-A, VEGF-B, VEGF-C and VEGF-D which are interacting with 
VEGF receptors such as VEGFR1, VEGFR2 and VEGFR3 (Lohela et al., 2009). The 
process of angiogenesis is mainly regulated by the VEGFA/VEGFR-2 system. VEGF 
contributes to the angiogenic response by enhancing microvascular permeability, 
improving endothelial cell proliferation, migration, survival and secretion of matrix 
metalloproteinases (MMPs) (Brychtova et al., 2008; Abhinand et al., 2016). 
VEGF-A is the basic regulator for vasculogenesis and regulates angiogenic sprouting 
(figure 1.7). It has been demonstrated that VEGF-A stimulated the migration of tip cells, 
while it induced proliferation in stalk cells (Gerhardt et al., 2003).  
  
 
 
 
 
 
 
 
Activation of VEGFR2 regulates major signaling pathways involved in vasculogenesis and 
angiogenesis. The binding of VEGF to VEGFR results in phosphorylation of a specific 
tyrosine in VEGFR2. VEGFR2 in the mouse is named fetal liver kinase-1 (Flk-1) while the 
Figure 1.7: VEGF signaling during sprouting. Brown color: soluble VEGFR1, red color: 
VEGFR2 and blue color: VEGF (Geudens and Gerhardt, 2011). 
 
Stalk cell 
Tip cells 
sVEGFR1 
VEGFR2 
VEGF 
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human VEGFR2 is referred to as kinase insert domain receptor (KDR) (Fuh et al. 1998; 
Shinkai et al., 1998). 
Vascular endothelial cadherin (VE-Cadherin) is the most important endothelial adhesion 
molecule which is located between endothelial cells at cell junctions. VE-Cadherin is 
essential for preservation of vascular system integrity and leukocyte extravasation 
(Vestweber, 2008).  
Endothelial cell-to-cell junctions do not just preserve intercellular adhesion, but 
additionally exchange intracellular signals that regulate cell differentiation (Dejana et al., 
2009). Other studies mentioned that VE-Cadherin is necessary for development of the 
cardiovascular system during embryo development as it controls vascular permeability and 
represses excessive vascular cell proliferation and branch formation (Breier et al., 1996; 
Crosby et al., 2005; Giannotta et al., 2013). 
 
HIF-1α is an oxygen sensing transcription factor which plays important roles in 
angiogenesis during mammalian embryonic and adult angiogenesis as well as in tumor 
angiogenesis. The activity of HIF-1α is regulated by different post-translational 
modifications (Lee et al., 2004). Growth factors increase HIF-1α protein translation so that 
HIF-1α contributes to the control of growth factor-induced glucose digestion even without 
hypoxia (Lum et al., 2007). 
 
1.14. Nitric oxide (NO) 
NO is a soluble gas synthesized enzymatically from the amino acid L-arginine in 
endothelial cells (Cannon, 1998; Kampoli et al., 2012). Many functions such as blood 
pressure, vascular tone and oxidant-sensitive mechanisms can be regulated by NO (Ignarro 
and Napoli, 2004). NO is reacting with oxygen, superoxide or metals, nucleic acids and 
proteins. During the cellular metabolism of NO, nitrate and nitrite can be formed by 
oxidation processes, and - especially under hypoxic conditions - can be recycled to form 
NO (Thomas et al., 2008; Lundberg and Weitzberg, 2009) (figure 1.8). The biological 
chemistry of NO is either direct or indirect, depending on its concentration in cells and 
tissues (Wink et al., 1996). In low concentrations NO is directly activating NO-sensitive 
signal cascades which regulate physiological cell functions. In high concentrations NO is 
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reacting with superoxide (O2
.−) or oxygen (Wink and Mitchell, 1998) to form peroxynitrite, 
which is a very reactive molecule and exerts severe oxidative stress under 
pathophysiological conditions. NO is generated by three different enzymes, namely 
inducible NO synthase (iNOS, NOSII), endothelial NO synthase (eNOS, NOSIII) and 
neuronal NO synthase (nNOS, NOSI) (Rochette et al., 2013).  
 
 
 
 
 
 
 
 
 
 
1.15. Signaling pathways involved in differentiation of ES cells  
1.15.1. Endothelial NO synthase (eNOS) 
eNOS is responsible for NO generation in the vascular system and has essential 
vasoprotective roles (Dimmeler et al., 1999; Jones et al., 2004; Edgar et al., 2017).  
eNOS derived NO keeps veins expanded, controls blood pressure and has various anti-
atherosclerotic impacts. Numerous cardiovascular risk factors induce oxidative stress by 
eNOS uncoupling, thus causing endothelial dysfunction in the vasculature (Förstermann 
and Sessa, 2012). The phosphorylation of eNOS (p-eNOS) occurs on serine (Ser1177) and 
threonine (Thr495) residues, and is fundamental for the activity of eNOS (Fleming and 
L-Arginine 
Nitric Oxide 
(NO) 
Direct 
effect 
Indirect 
effect 
Oxidation 
Reduction 
Nitric Oxide 
(NO) 
 
Nitrate & Nitrite 
NO3
-
/NO2
-
 
 
Figure 1.8: Schematic view of NO generation. Direct effect: NO can originate from L-
arginine and oxygen by NO synthases; indirect effect: Nitrate and Nitrite are reduced to 
make NO. 
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Busse, 2003). eNOS has been shown to be inhibited by N
G
 -nitro-L-argininemethyl-ester 
(L-NAME) (Pfeiffer et al., 1996; Isenberg, 2003; Lu et al., 2015), which depressed the 
inflammatory reaction exerted by pro-inflammatory cytokines (Isenberg, 2003).  
 
1.15.2. AKT signaling pathway 
AKT (protein kinase B) kinase acts downstream of PI3K, AKT kinase controls cellular 
processes such as cell proliferation, survival, cell size, response to nutrient availability, 
tissue invasion and angiogenesis (Scheid and Woodgett, 2003; Bellacosa et al., 2005). In 
vitro, AKT activation is important for the survival and propagation of vascular progenitor 
cells generated from mouse ES cells. In vivo, AKT maintained endothelial cell identity in 
embryonic vessels that anastomose with vessels of the host (Israely et al., 2014). The 
phosophorylation of AKT (p-AKT) occurs at Ser473, and AKT inhibitor VIII specifically 
inhibited the AKT pathway, as well as down-regulated active AKT (Alessi et al., 1996; 
Bayascas and Alessi, 2005; Peng et al., 2010). 
 
1.15.3. Signal transducer and activator of transcription 3 (STAT3) signaling pathway  
The transcription factor STAT3 is initiated by numerous cytokines and growth factors and 
plays a key function in cell survival, proliferation and differentiation (Wang et al., 2011). 
During infection, released IL-6 participates in induction of STAT3 kinase. Other studies 
suggested that STAT3 kinase exerts a substantial role in early developmental stages of 
embryogenesis (Levy and Lee, 2002). STAT3 is an important key in transcriptional 
determination of mouse ES cell self-renewal. Moreover, the development of many organs 
needs the activation of STAT3 (Xie et al., 2009). 
 
1.15.4. Phosphatidylinositol-3-kinase (PI3K) signaling pathway 
PI3K has an important role in cell stimulation to initiate cell growth, cell cycle, cell 
migration, cell survival cascades, cell metabolism and the control of gene expression. PI3K 
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induced NO production in endothelial cells (Cantley, 2002; Isenović et al., 2002). 
Furthermore, PI3K has a fundamental role in the treatment of obesity (Beretta et al., 2015), 
since PI3K-mediated cell survival was activated by unregulated signaling of the AKT 
pathway (Shiojima and Walsh, 2002). PI3K comprises of four classes (IA, IB, II and III) 
dependent on their structural characteristics; all types of PI3K contain a C2 domain and a 
catalytic domain that is not found in protein kinases but is present in lipid kinases (Koyasu, 
2003). The PI3K subunit p110α plays an important role in VEGF-regulated vascular 
differentiation and the control of cell polarity and migration (Bekhite et al., 2016). In vitro, 
the PI3K/AKT pathway is crucial for hypoxia-induced proliferation of bone marrow-
derived mesenchymal stem cell, their differentiation into endothelial cells and paracrine 
functions (Sheng et al., 2017). 
 
1.16. Leukocyte differentiation (Leukopoiesis) from ES cells 
In the adult, the hematopoietic system arises from bone marrow hematopoietic stem cells. It 
consists of erythrocytes, leukocytes (neutrophils, basophils, eosinophils, lymphocytes, 
monocytes, macrophages) and platelets (Dzierzak and Speck, 2008). Leukocytes belong to 
the cellular immune system and participate in the defense against infection, allergy and 
inflammation. In addition, leukocytes are involved in advancement and determination of 
inflammation, elimination of apoptotic cells, support of cell proliferation and tissue 
rebuilding following damage (Koh and DiPietro, 2011). 
During embryogenesis, hematopoietic and endothelial cell lineages develop from a 
common precursor which contains intermediate stages between mesodermal cells and 
committed precursors for hematopoietic and endothelial cell lineages (Ogawa et al., 2001). 
There are two types of hematopoietic cell lineages which are different in origin, one of 
them derives from hemangioblasts and is called primitive hematopoietic lineage. The other 
originates from endothelial cells, and is called definitive hematopoietic lineage (Ogawa et 
al., 2001). 
In vitro, ES cells differentiate towards hematopoietic progenitors which can be used for 
basic and clinical research applications. Recently, it has been demonstrated that pluripotent 
ES cells are able to differentiate to the endothelial cell lineage as well as into hematopoietic 
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lineages such as leukocytes (monocytes/macrophages) (Choi et al., 2005; Shen and Qu, 
2008). Hematopoietic progenitors derived from EBs express high numbers of CD45
+
 cells 
and - when cultured in presence of cytokines - are capable to differentiate to macrophages. 
(Subramanian et al., 2009), T lymphocytes (T-cell), neutrophil cells, natural killer (NK) 
cells and dendritic cells (Liang et al., 2013; Lieber et al., 2003; Luevano et al., 2012; Tseng 
et al., 2009). A previous study of our group has demonstrated that ES cells differentiated 
vascular cells as well as leukocytes, including monocytes/macrophages and neutrophils 
(Hannig et al., 2010; Sharifpanah et al., 2015). Leukopoiesis from ES cells follows 
vasculogenesis in a time-controlled manner and can be inhibited if vasculogenesis is 
blunted by antagonists of the VEGFR2 signaling pathway (Hannig et al., 2010, Sharifpanah 
et al., 2015). 
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Aims of study: 
 
The milk thistle compound Silibinin is stimulating regenerative processes which may 
involve the activation of stem cells. The present study undertakes to investigate the effect 
of Silibinin (Silibinin-C-2’, 3-dihydrogen succinate, disodium salt) on cardiovascular 
differentiation as well as leukopoiesis of mouse ES cells. 
 
Specifically the following goals were pursued: 
 
1- To study the effect of Silibinin on cardiomyogenesis of ES cells and cardiac cell 
function. 
 
2- To unravel the effect of Silibinin on the stimulation of cardiomyogenesis and 
cardiac cell function by Ang II. 
 
3- To investigate the effect of Silibinin on vasculogenesis of ES cells. 
 
4- To decipher NO-mediated signaling pathways underlying the stimulation of 
vasculogenesis by Silibinin. 
 
5- To assess, whether Silibinin stimulates leukopoiesis from ES cells. 
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2. Materials and methods 
2.1. Materials 
2.1.1. General materials 
Table 1: Materials 
Materials Supporting Company 
24 well cell culture plate Sarstedt, Nümbrecht, Germany 
6 well cell culture plate Sarstedt, Nümbrecht, Germany 
96 well flat bottom tissue plate Sarstedt, Nümbrecht, Germany 
Bacterial culture dish Sarstedt, Nümbrecht, Germany 
Cellspin Integra Biosciences, Chur, Switzerland 
Conical flasks 
Fischer Scientific GmbH, Schwerte, 
Germany 
Conical tubes 15ml, 50ml 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cover slips 
Deckgläser, Menzel-Gläser, Darmstadt, 
Germany 
Eppendorf tubes Sarstedt, Nümbrecht, Germany 
Filter paper for blotting 
Universal, Biotech Fischer, Reiskirchen, 
Germany 
Glass pasteur pipettes Brand GmbH, Wertheim, Germany 
Glass slides R. Langenbrinck GmbH, Emmendingen, 
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Germany 
Gloves 
Paul Hartmann AG, Heidenheim, 
Germany 
Gloves Micro-Touch (Nitra-Tex)  Ansell, Brussels, Belgium 
Immersion oil Leica Microsystems, Wetzlar, Germany  
Optical microscope TELAVAL 31 Carl Zeiss, Jena, Germany 
PAGEr EX mini-Gels Lonza, Rockland, USA 
Parafilm 
Bemis Flexible Packaging, Neenah, 
USA 
Pipette filter tips 
Biozym Scientific, Hessisch Oldendorf, 
Germany 
Pipette tips Sarstedt, Nümbrecht, Germany 
PVDF millipore transfer 
membrane 
Merck Millipore, Darmstadt, Germany 
Serological glass 
pipettes 
ISO Lab, Wertheim, Germany 
Serological glass 
pipettes, wide tip 
Corning, New York, USA 
Serological plastic 
pipettes 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Spinner flask (250ml) Integra Biosciences, Fernwald, Germany 
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Sponge Pad for blotting 
Invitrogen by Thermo Fisher Scientific, 
Darmstadt, Germany 
Tissue culture plate 
(60mm, 150 mm) 
Sarstedt, Nümbrecht, Germany 
 
 
2.1.2. Instruments 
Table 2: Instruments 
Instruments Supporting Company 
-20ºC freezer 
Thermo Fisher Scientific, Darmstadt, 
Germany 
-80ºC freezer Heraeus, Hanau, Germany 
4ºC refrigerator Siemens, Munich, Germany 
Autoclave Holzner GmbH, Nussloch, Germany 
Blotting chamber, Xcell II Blot module Life Technologies, Darmstadt, Germany 
Cell culture incubator (Heracell) Heraeus, Hanau, Germany 
Centrifuge (Eppendorf 5417C) Eppendorf AG, Hamburg, Germany 
Centrifuge (Multifuge 1S-R) Heraeus, Hanau, Germany 
Chemiluminescence imaging system 
PeQLab Bitechnologie GmbH, Chemi-
Capt-50001, Erlangen, Germany 
Confocal laser scanning microscope SP2, Leica, Wetzlar, Germany 
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AOBS 
Electrophoresis chamber (Xcell SureLock 
Mini-Cell) 
Invitrogen by Thermo Fisher Scientific, 
Darmstadt, Germany 
FireBoy portable safety Bunsen burner Integra Biosciences, Fernwald, Germany 
Gel electrophoresis high voltage power 
supply 
Invitrogen by Thermo Fisher Scientific, 
Darmstadt, Germany 
Gel electrophoresis power station 
Invitrogen by Thermo Fisher Scientific, 
Darmstadt, Germany 
Heating block or TB2 Thermoblock, Biometra, Göttingen Germany 
Homogenizer Sigma-Aldrich, Taufkirchen, Germany 
Ice machine (Icematic F200) Castel MAC, Castelfranco Veneto, Italy 
Laminar flow cabinet, class II biological 
safety 
Heraeus, Hanau, Germany 
Light microscope Zeiss, Jena, Germany 
Liquid nitrogen and cryopreservation storage 
tank 
Air Liquide Global E&C, Vitry-sur-
Seine, France 
Magnetic stirrer IKA RH-KT/C, Staufen, Germany 
Magnetic stirrer for spinner flask (Cellspin) Integra Biosciences, Fernwald, Germany 
Microplate ELISA reader, Infinite M200 
Tecan Austria GmbH Model, 
Männedorf, Switzerland 
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Microscope heating stage TRZ 3700 Labexchange, Burladingen,Germany 
Milli-Q Advantage A10 System Merck Millipore, Darmstadt, Germany 
pH-meter 
Hanna Instruments, Kehl am Rhein, 
Germany 
Shakers 
Heidolph Elektro GmbH, Schwabach, 
Germany 
Tube roller mixer Stuart, London, UK 
Vacuum pump 
HLC BioTech, Bovenden Germany 
Vortex (Vortex genie 2) VWR, Darmstadt, Germany 
Water bath Lauda, Lauda-Königshofen, Germany 
Weighing machines 
(TE153S, AB265S) 
Sartorius AG, Göttingen, Germany  
Meltter toledo, Columbus, USA 
 
2.1.3. Solutions and chemical materials 
Table 3: Solutions and chemical materials 
Materials Supporting Company 
Acetic acid Sigma-Aldrich, Taufkirchen, Germany 
Copper sulfate  Sigma-Aldrich, Taufkirchen, Germany 
DAF-FM diacetate  
Invitrogen by Life Technologies, 
Darmstadt, Germany 
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Dimethyl sulfoxide (DMSO) Merck Millipore, Darmstadt, Germany 
Di-Sodium hydrogen phosphate dihydrate Carl Roth, Karlsruhe, Germany 
Dulbecco’s PBS without Ca2+ & Mg2+ PAA, Cölbe, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Ethanol Carl Roth, Karlsruhe, Germany 
Fluo-4-AM 
Invitrogen by Life Technologies, 
Darmstadt, Germany 
Fluoromount-G Southern Biotech, Birmingham, USA 
Hydrogen peroxide solution (30%) Sigma-Aldrich, Taufkirchen, Germany 
Luminol Sigma-Aldrich, Taufkirchen, Germany 
Methanol Carl Roth, Karlsruhe, Germany 
Novex Sharp pre-stained protein standard  Life Technologies, Darmstadt, Germany 
NuPAGE antioxidant 
Invitrogen, Thermo Fisher Scientific, 
Darmstadt, Germany 
NuPAGE LDS sample buffer (4X) 
Invitrogen, Thermo Fisher Scientific, 
Darmstadt, Germany 
NuPAGE reducing agent (10X) 
Invitrogen, Thermo Fisher Scientific, 
Darmstadt, Germany 
Paraformaldehyde (PFA) Carl Roth, Karlsruhe, Germany 
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P-coumaric acid Sigma-Aldrich, Taufkirchen, Germany 
Phosphatase inhibitor cocktail 3 Sigma-Aldrich, Taufkirchen, Germany 
Ponceau S AppliChem, Darmstadt, Germany 
Potassium chloride Carl Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate Carl Roth, Karlsruhe, Germany 
ProSieve EX running buffer Lonza, Rockland, USA 
ProSieve EX transfer buffer Lonza, Rockland, USA 
Protease inhibitor cocktail BioVision, Milpitas, USA 
Restore PLUS western blot Stripping Buffer 
Thermo Fisher Scientific, Darmstadt, 
Germany 
Sigmacote Sigma-Aldrich, Taufkirchen, Germany 
Sodium carbonate Carl Roth, Karlsruhe, Germany 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodium potassium tartrate Merck Millipore, Darmstadt, Germany 
Sterile distilled water  
Braun Melsungen AG, Melsungen, 
Germany 
Tris base Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Sigma-Aldrich, Taufkirchen, Germany 
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Tween-20 Sigma-Aldrich, Taufkirchen, Germany 
 
2.1.4. Cell lines  
CCE S103 cell line, mouse ES cell line isolated from embryos mouse strain129/sv 
(Robertson et al., 1986).  
 
2.1.5. Cell culture media components and substances 
Table 4: Cell culture media components and substances 
Substances Supporting Company 
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
Ang II Sigma-Aldrich, Taufkirchen, Germany 
Collagenase B Roche, Mannheim, Germany 
Dulbecco´s modified Eagle medium 
(DMEM) 
Biochrom, Berlin, Germany 
EmbryoMax 0.1% gelatin solution Merck Millipore, Darmstadt, Germany 
ESGRO mouse LIF medium Chemicon, Hampshire, UK 
Fetal bovine serum  Sigma-Aldrich, Taufkirchen, Germany 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) 
Biochrom, Berlin, Germany 
L-Glutamine 200mM (100X) Biochrom, Berlin, Germany 
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2.1.6. Inhibitors 
Table 5: Inhibitors 
Inhibitors 
Final 
concentration 
Dissolve 
in 
Supporting Company 
AKT inhibitor 
VIII  5µM DMSO 
STEMCELL Technologies, 
Vancouver, Canada. Cat. No. 72942  
L-NAME (eNOS 
inhibitor)  
100µM water 
Sigma-Aldrich, Deisenhofen, 
Germany. Cat. No. 51298-62.5 
LY294002 (PI3K 
inhibitor) 
5µM DMSO 
InvivoGen, San Diego, CA, USA 
Cat. No. tlrl-ly29 
Stattic (STAT3 
inhibitor) 
7µM DMSO 
TOCRIS Biosciences, Bristol, UK. 
Cat. No. 19983-44-9 
 
Mitomycin-C Merck Millipore, Darmstadt, Germany 
NEA-non-essential amino acids (100X) Biochrom, Berlin, Germany 
Non-fat dried milk powder 
AppliChem GmbH, Darmstadt, 
Germany 
Penicillin/Streptomycin (100X)  Biochrom, Berlin, Germany 
Plasmocin prophylactic  InvivoGen, California, USA 
Silibinin (Silibinin-C-2’, 3-dihydrogen 
succinate, disodium salt (Legalon Sil)) 
Meda Pharma, Bad Homburg, Germany 
Trypsin EDTA 1X Life Technologies, Darmstadt, Germany 
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2.2. Media and buffers 
2.2.1. Media 
 
2.2.1.1. CCE Complete medium 
- IMDM high glucose medium  1X 
- Heat inactivated fetal calf serum   16% 
- - mercaptoethanol   0.1mM 
- Sodium pyruvate (100mM)   1.0mM 
- L- Glutamine (200mM)  2.0mM 
- Non-essential amino acids (100mM)  0.1mM 
- Penicillin/Streptomycin (10000U/ml)  50U/ml 
 
2.2.1.2. EMFI medium 
- DMEM high glucose medium  1X 
- Heat inactivated fetal calf serum  10% 
- - mercaptoethanol   0.1mM 
- Sodium pyruvate (100mM)   1.0mM 
- L- Glutamine (200mM)  2.0mM 
- Non-essential amino acids (100mM)  0.1mM 
- Penicillin/Streptomycin (10000U/ml)  50U/ml 
 
2.2.1.3. LIF medium 
- IMDM high glucose medium  1X 
- Heat inactivated fetal calf serum  16% 
- - mercaptoethanol  0.1mM 
- Sodium pyruvate (100mM)  1.0mM 
- L- Glutamine (200mM)  2.0mM 
- Non-essential amino acids (100mM)  0.1mM 
- ESGRO LIF  1000U/ml 
 
2.2.1.4. LIF pLpro medium  
- LIF medium  50ml 
- Plasmocin prophylactic  2.5µg/ml 
 
2.2.1.5. Medium for feeder cell freezing  
- EMFI medium  50% 
- Heat inactivated fetal calf serum   40%  
- DMSO   10% 
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2.2.2. Buffers and other solutions 
 
1x PBS 
- KCl  2.7mM 
- KH2PO4  1.8mM 
- NaCl  137mM 
- Na2HPO4 2H2O  10mM 
            adjust pH to 7.4  
 
1% PBST 
- 1x PBS   100ml 
- Triton X-100  1ml 
 
0.01% PBST 
- 1x PBS  100ml 
- Triton X-100  10µl 
 
0.01% PBST Tween-20  
- 1x PBS  100ml 
- Tween-20   10µl 
 
1x TBS 
- Tris base  50mM  
- NaCl  150mM 
            adjust pH to 7.6  
  
0.1% TBST  
- 1x TBS  100ml 
- Tween-20   100µl 

- mercaptoethanol solution (10mM) 
- 1x PBS   50ml 
- - mercaptoethanol (stock 14mM)   35µl 
 
Lowry Solution (stock concentration) 
  
- Lowry Solution 1 Na-K-Tartrate     117mM 
- Lowry Solution 2 Cu2CO4    50mM 
- Lowry Solution 3 Na2CO3    2.4M 
 
Lowry Solution 4  
- NaOH   1M 
 
Lowry Solution 5 
- Folin-Ciocalteu’s phenolreagent (Merck 9001) ~ 0.5N 
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RIPA buffer 
- Tris, pH 7.4  50mM 
- NaCl  150mM 
- Nonidet P-40  1% 
- Sodium dodecyl sulfate (SDS)  0.1%  
Deoxycholate (excluded in phospho-protein assays)  0.5% 
 
 
Lysis solution for protein extraction  
- RIPA buffer  1x 
- Protease inhibitor cocktail  1x 
 
 
Lysis solution for phospho-protein extraction  
- RIPA buffer  1x 
- Protease inhibitor cocktail  1x 
- Phosphatase inhibitor cocktail  1x 
- Glycerophosphate   1mM 
- EDTA, pH 8  1mM 
 
 
Ponceau staining solution  
- Ponceau S   0.1% (w/v)  
- Acetic acid 1% (v/v) 
 
 
Paraformaldehyde fixing solution (4% PFA) 
- 1x PBS  1 Liter 
- PFA  40g 
           adjust pH to 6.9 with 1N NaOH   
 
Blocking solution 
10% milk 
- Non-fat dried milk powder  10g 
- 0.01% PBST  100ml 
 
5% milk 
- Non-fat dried milk powder   5g 
- 0.01% TBST  100ml 
 
 
Enhanced Chemi-Luminescence (ECL) detection solution 
- Tris–HCl , pH 8.5  100mM 
- Hydrogen peroxide solution (30%) (v/v)  3mM  
- Luminol    1.25mM 
- Cumaric acid  225µM 
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2.2.3. Antibodies 
Table 6: A- Antibodies for immunohistochemistry 
Primary antibody  
 Antibodies Company Cat. No. 
Mouse anti-mouse -actinin Abcam, Cambridge, UK ab9465 
Rat anti-mouse CD31 
Merck Millipore, 
Darmstadt, Germany 
LV1815894 
Leukocyte markers   
Rat anti-mouse CD18   
Biolegend, Koblenz, 
Germany 
101409 
Rat anti-mouse CD45 
Merck, Darmstadt, 
Germany 
2395751 
Rat anti-mouse CD68 
Bio Rad (AbD Serotec), 
Düsseldorf, Germany 
0713 
Secondary antibody   
Alexa Fluor 488 donkey anti-rat IgG 
Life Technologies, 
Darmstadt, Germany 
A-21208 
DyLight 650 goat anti-rat IgG Abcam, Cambridge, UK ab98408 
Cy5-conjugated goat anti-rat IgG 
Jackson ImmunoResearch, 
West Grove, PS, USA 
712-176 
Alexa Fluor 647 sheep anti-mouse IgG  
Jackson ImmunoResearch, 
West Grove, PS, USA 
 515-605-072 
Nuclear staining   
DRAQ5 
Cell Signaling Technology, 
Danvers, USA 
4084 
 
Materials and Methods 
 
32 
 
Table 7: B- Antibodies for western blot 
Primary antibody  
 Antibodies Company Cat. No. 
Weight 
(KDa) 
Endothelial cell markers    
Rat anti-mouse VE-Cadherin 
(CD144) 
BD Biosciences GmbH, 
Heidelberg, Germany 
555289 115 
Progenitor marker     
Rabbit anti-mouse Flk-1 
(VEGFR2) 
Cell signaling Technology, 
Danvers, USA 
8324 230 
Rabbit anti-mouse Flk-1 
(VEGFR2) 
Biorbyt, Biozol, Eching, 
Germany 
Orb11556 147 
Hypoxia marker     
Mouse anti- HIF-1 67) 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
D1913 120 
House-keeping proteins    
Mouse anti-Vinculin 
Sigma-Aldrich, 
Taufkirchen, Germany 
V9131 110 
Rabbit anti-GAPDH Abcam, Cambridge, UK ab22555 36 
Rabbit anti β-actin  
Biolegend, Koblenz, 
Germany 
622102 45 
Materials and Methods 
 
33 
 
Leukocyte markers    
Rat anti-mouse CD18  
Biolegend, Koblenz, 
Germany 
101409 95 
Rat anti-mouse CD45 
Novus Biologicals, 
Wiesbaden Nordenstadt, 
Germany  
15811 147 
Rat anti-mouse CD68 
Bio Rad (AbD Serotec), 
Düsseldorf, Germany 
MCA1957
GA 
110 
Phosphoproteins    
Mouse anti-p-STAT3 (Ser722) 
Cell signaling Technology, 
Danvers, USA 
9136S 86 
Rabbit anti-p-AKT (Ser473)  
Biolegend, Koblenz, 
Germany 
649002 60 
Rabbit anti-p-eNOS (Ser1177)  
Cell signaling Technology, 
Danvers, USA 
9571S 140 
Rabbit anti-p-ERK1/2 
(Thr202/Tyr204)  
Cell signaling Technology, 
Danvers, USA 
9101 42, 44 
Rabbit anti-p-JNK 
(Thr183/Tyr185)  
Cell signaling Technology, 
Danvers, USA 
9251S 46, 54 
Rabbit anti-p-p38 MAP Kinase 
(Thr180/Tyr182)  
Cell signaling Technology, 
Danvers, USA 
9211 43 
Rabbit anti-p-PI3K p85 
(Tyr458)/p55 (Tyr199)  
Thermo Fisher Scientific, 
Darmstadt, Germany 
PA5-
17387 
60, 85 
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Rabbit anti-p-VEGFR2 (p-
Tyr951) 
Biorbyt, Biozol, Eching, 
Germany 
Orb106137 152 
Total protein markers    
Rabbit anti-eNOS 
Sigma-Aldrich, 
Taufkirchen, Germany 
N3893 135 
Rabbit anti-PI3K 
Cell signaling Technology, 
Danvers, USA 
4292S 85 
Secondary antibody    
HRP-linked donkey anti-goat IgG 
Abnova, Heidelberg, 
Germany  
PAB10570  
HRP-linked goat anti-rabbit IgG 
Cell signaling Technology, 
Danvers, USA  
7074  
HRP-linked donkey anti-rabbit 
IgG 
Abcam, Cambridge, UK ab205722  
HRP-linked goat anti-rat IgG 
Cell signaling Technology, 
Danvers, USA 
7077  
HRP-linked donkey anti-rat IgG Abcam, Cambridge, UK ab102265  
HRP-linked horse anti-mouse IgG 
Cell signaling Technology, 
Danvers, USA 
7076  
HRP-linked donkey anti-mouse 
IgG 
Abcam, Cambridge, UK ab20524  
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2.2.4. Fluorescence substances 
2.2.4.1. DAF-FM 
DAF-FM diacetate (4-amino-5-methylamino-2',7’- difluorofluorescein diacetate) is a 
reagent which is used for the detection of NO. It is non-fluorescent, but when reacting with 
NO, becomes a fluorescent benzotriazole, and can be detected by fluorescent microplate 
readers, fluorescence microscopy and flow cytometers (Itoh el al., 2000). Maximum 
excitation wavelengths of the oxidized form is at 495nm and fluorescence emission is 
detected at wavelengths > 515nm. DAF–FM is dissolved in DMSO. 
 
2.2.4.2. Fluo-4-AM 
Fluo-4 is utilized to quantify Ca
2+
 inside living cells. It is regularly utilized as the non-
fluorescent acetoxymethyl ester (Fluo-4-AM) which is cleaved inside the cell by cellular 
esterases to give a free, fluorescent Fluo-4. Fluo-4 is excited at 488nm, and emission is 
recorded at > 515nm. 
 
2.2.4.3. DRAQ5 
DRAQ5 (1, 5-bis{[2-(di-methylamino)ethyl] amino}-4, 8-dihydroxyanthracene-9, 10-
Dione) is a cell permeable far-red fluorescent DNA dye that can be applied in fixed or non-
fixed/ live cells. DRAQ5 is excited at 633nm, and emission is rercorded at > 655nm. 
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2.3. Methods 
2.3.1. Cell culture 
2.3.1.1. Thawing mouse embryonic fibroblasts (MEFs)  
MEFs are used as feeding layer for proliferating ES cells, since they secrete LIF which 
inhibits ES cell differentiation. First of all LIF plasmocin prophylactic medium was 
warmed in 37°C water bath, and 5ml medium was distributed in 60mm cell culture plates 
and incubated in a (37°C and 5% CO2) incubator. 
Vials of MEFs frozen in a liquid nitrogen tank (-196°C) were thawed in water bath at 37°C. 
Subsequently MEFs cells were transferred into a 50ml conical tube containing 20ml of 
warmed EMFI medium and centrifuged for 5 min at 209g at RT. The supernatant was 
removed, and the pellets were resuspended in equal volumes of warmed EMFI medium and 
seeded in 60mm cell culture plates which were transferred to a CO2 incubator. 
The mitotic inactivation of MEFs is started by the replacement of the growth medium 
with 3ml medium containing mitomycin C in a concentration of 10µg/ml and incubation for 
3h (Verweij and Pinedo, 1990). To stop the inactivation process, the mitomycin containing 
medium was aspirated, cells were washed 3 times with EMFI medium, and were incubated 
in 5ml of fresh EMFI medium (figure 2.1). 
 
 
 
 
 
 
 
 
 
 
 
2.3.1.2. Thawing of ES cells  
Vials of ES cells frozen in liquid nitrogen were rapidly thawed in water bath at 37°C. The 
cell suspension was transferred to a 50ml conical tube containing 20ml pre-warmed CCE-
Figure 2.1: Transmission image of confluent MEFs, The bar represents 100μm. 
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medium and centrifuged for 5 min at 209g at RT. Subsequently the supernatant was 
removed and the cell pellet resuspended with 200µl of pre-warmed CCE-medium. The 
thawed ES cells were seeded at a density of 9 x 10
4
 cells/ml onto confluent, mitomycin C-
inactivated MEFs in 60mm cell culture dishes and further incubated in a CO2 (5%) 
incubator at 37°C (Kent, 2009). 
 
2.3.1.3. Passaging of ES cells 
ES cells were grown on inactivated MEFs until 70% sub-confluency. The medium 
containing LIF was changed every 24h. Every 2 days, the cells were passaged by enzymatic 
dissociation. Briefly, the cell culture medium was removed and ES cell cultures were 
washed with 2ml pre-warmed trypsin-containing dissociation medium. After aspiration, 
2ml warm trypsin-containing dissociation medium was added, and the cells were further 
incubated at 37°C and 5% CO2. Subsequently ES cell colonies were further dissociated by 
gently pulling up and down with a 1ml pipette to obtain single cells suspension. A number 
of 9 x 10
4
 ES cells/ml was added to each MEF plate and further incubated in the CO2 
incubator (figure 2.2) (Tamm et al., 2013).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Colonies of mouse ES cells growing on mitotically inactivated MEFs, A- 
Feeder layer of MEFs, B- Colonies of undifferentiated mouse ES cells. The bar represents 
100μm. 
A 
B 
Materials and Methods 
 
38 
 
2.3.1.4. Preparation of spinner flask (cleaning and siliconizing) 
Spinner flasks were washed with distilled water and subsequently filled with 250ml of 70% 
ethanol for 30 min. Then, 5N NaOH was added for 8 to 12h; the flasks were washed with 
water, and left for drying. 
The purpose of silicon coating is, to prevent the cells from adhesion to the interior glass 
wall prior to the formation of EBs. The spinner flask and magnetic stirring bars were coated 
by silicon solution (Sigmacote). The silicon coated spinner flask should be dried in the 
oven at 60°C for 1h. Finally, the spinner flask was washed three times with distilled water 
before autoclaving. 
 
2.3.1.5. Generation of embryoid bodies (EBs) 
In suspension culture and absence of LIF, ES cells aggregate together and form three-
dimensional (3D) tissues, named EBs (Bratt-Leal et al., 2009). After coating and 
autoclaving, spinner flasks were washed with pre-warmed cell culture medium, filled with 
a volume of 125ml medium, and placed on a magnetic stirring plate in the incubator as 
shown in (figure 2.3-A). ES cells grown on MEFs were enzymatically dissociated as 
described and seeded in the spinner flask at a cell density of 3 x 10
6
 cells/ml. On the 
following day another 125ml medium was added to the spinner flask to give a final volume 
of 250ml. The speed of the magnetic stirrer system was set to 25 r.p.m. The spinning 
direction was changed every 1440°. In general, 3-day-old EBs cultivated in spinner flasks 
(figure 2.3-B) were used for the experiments.  
 
2.3.1.6. Freezing of ES cells 
For freezing purposes, confluent mouse ES cell culture plates (60mm) were washed and 
incubated with 2ml of trypsin for 2 min in the incubator. The dissociated cell suspension 
was transferred into 20ml of pre-warmed medium to stop enzymatic digestion, and was 
centrifuged for 5 min at 209g. The supernatant was aspirated and cell pellets cooled on ice. 
Finally, 1ml of cell freezing medium (4°C) was slowly added to the pellets, gently mixed, 
immediately transferred to 1.8ml labeled cryopure vials and frozen in a -80°C freezer prior 
to long term storage in liquid nitrogen tank. 
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2.3.2. Treatment protocol for Silibinin  
To explore the effect of Silibinin on mouse ES cells, EBs were removed from spinner 
flasks at day 3 of cell culture and 25-30 EBs were transferred in either 60mm bacterial 
culture plates or tissue culture plates containing 5ml medium. Treatment with Silibinin at 
different concentrations ranging from 1-50µM was performed from day 3 to day 10 of 
differentiation to investigate the effect of Silibinin on vasculogenesis and 
cardiomyogenesis. For the investigation of leukopoiesis, EBs were treated with Silibinin 
from day 3 to day 14 of cell culture. Cell culture medium containing Silibinin was 
exchanged every 24h. After the incubation period, EBs for vasculogenesis and 
cardiomyogenesis were either fixed in ice-cold methanol to perform 
immunohistochemistry, while for the investigation of leukopoiesis EBs were fixed in 4% 
PFA or protein was extracted for western blot experiments (figure 2.4). 
 
 
 
Figure 2.3: Spinner flask and EBs (A) Spinner flask on top of a magnetic stirring plate. 
Two glass pendula are rotating with a speed of 25 r.p.m. The spinning direction is changed 
every 1440°. (B) Transmission image of EBs at day 3 of cell culture. The bar represents 
100μm. 
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Figure 2.4: Basic Steps of experiments. A-Vasculogenesis in 10-day-old EBs, the bar 
represents 300μm. B- Cardiomyogenesis in 10-day-old EBs, the bar represents 100μm. C- 
Leukopoiesis in 14-day-old EBs, the bar represents 75μm. 
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2.3.3. Measurement of contraction frequency of EBs 
The contraction frequency of EBs was assessed from day 7 to day 10 of cell culture by 
visual inspection using a light microscope (Zeiss Axiovert 40 C) which was connected to a 
microscope heating stage TRZ 3700 and equipped with a 5/0,12-x objective (CP-Achromat, 
Zeiss). The frequency of spontaneously contractions in EBs was counted at 37 °C for a time 
period of 1 min. At least 20 EBs were investigated in each experiment. At least 4 
experiments were performed with EB cultures from different passages.  
 
2.3.4. Immunohistochemistry (IHC) 
IHC is an important technique used for distinguishing antigens (e.g. proteins) in cells by 
specific binding of antibodies to antigens in natural tissues (Ramos-Vara and Miller, 2014).  
  
2.3.4.1. PECAM-1 (CD31) staining 
PECAM-1 (CD31) staining was performed to visualize three dimensional vascular 
networks in EBs.  
1-Sample collection: 10-day-old EBs were collected in microcentrifuge tubes, and the 
medium was aspirated before washing EBs 3 times with 1x PBS.  
2- Fixation: EBs were covered with ice-cold methanol and kept at -20°C for 20 min. 
3- Permeabilization: After fixation, the EBs were washed 4 times with 0.01% PBST 
(Triton-X-100) buffer, permeabilized with 1% PBST and incubated at RT for 10 min on the 
shaker. 
4- Blocking: After 10 min, the EBs were washed 4 times with 0.01% PBST buffer and 
were further incubated for 1h at RT on the shaker in 0.01% PBST buffer containing 10% 
milk powder.  
5- Primary Antibody: After blocking, EBs were washed 4 times with 0.01% PBST buffer. 
The primary antibody against PECAM-1 was freshly prepared by diluting 1:100 in 10% 
milk and incubated either at RT on the shaker for 2h or overnight at +4°C. 
6- Secondary Antibody: The EBs were washed 4 times with 0.01% PBST buffer and left 
10 min on the shaker at RT with 0.01% PBST buffer to ensure the removal of surplus 
primary antibody. The secondary antibody anti-rat Alexa 488 was added at a dilution of 
1:100 in 10% milk, and EBs were incubated for 1h in the dark at RT. Then they were 
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washed 4 times with 0.01% PBST and taken for imaging or stored at +4ºC with 4% PFA 
until analysis. 
7- Imaging: The stained EBs were transferred to the chamber slide, and the branching 
points were analyzed by confocal microscopy (Leica SP2 AOBS). The
 
pinhole settings of 
the confocal setup were adjusted to give
 
a full-width half maximum of 5µm. For the 
quantification of capillary areas within EBs an optical sectioning routine based on confocal 
laser scanning microscopy was used. Images (512 x 512 pixels) were acquired from 
PECAM-1 stained EBs using the extended depth of focus algorithm of the confocal setup. 
In brief, 10 full frame images, separated
 
by a distance of 10µm in z-direction, were 
recorded
 
that included the information of the capillary area and spatial
 
organization in a 
tissue slice 100µm thick.  
8- Analysis: The
 
acquired images were processed to generate a single in-focus image 
projection of vascular structures in the scanned tissue
 
slice. By use of the image analysis 
software Metamorph (Molecular Devices), the branching points of vascular structures 
within the three-dimensional projection were identified and counted in relation to the size 
(µm
2
) of the respective EB. 
 
2.3.4.2. -actinin staining 
-actinin staining was performed to visualize differentiated cardiac areas in EBs outgrown 
on cover slips and collected between day 7 and day 10 of cell culture. 
1- Sample collections: Cell culture medium was removed from EB tissue cultures. The 
medium was removed, and they were washed 3 times with 1x PBS. 
2- Fixation: The cells were fixed in ice-cold methanol and kept at -20°C for 20 min. 
3- Blocking: After fixation the cells were washed 4 times with 0.01% (Triton-X-100) 
PBST buffer containing 10% FCS and further incubated for 1h at RT. 
4- Primary Antibody: After blocking, cells were washed 4 times with 0.01% PBST buffer. 
The primary antibody against -actinin was diluted 1:100 in 10% FCS and incubated 
overnight at +4°C. 
5- Secondary Antibody: The EBs were washed 4 times with 0.01% PBST buffer and left 
10 min on the shaker with 0.01% PBST buffer to ensure the removal of surplus primary 
antibody. The secondary antibody Cy5 sheep anti mouse diluted 1:100 in 10% FCS was 
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added, and cells were incubated for 1h in dark at RT. EBs were washed 4 times with 0.01% 
PBST and stored at +4ºC until analysis time by embedding EBs on cover slips with 
Fluoromount-G. 
6- Imaging: The stained EBs were transferred to the stage of the Leica confocal 
microscope and α-actinin-positive cell areas were analysed using 10x objective and z- 
series.  
7- Analysis: Sizes of -actinin positive areas (µm²) in EBs were calculated by use of the 
image analysis software Metamorph. 
 
2.3.4.3. Leukocyte marker staining 
For Leukocyte marker staining, the EBs were treated with Silibinin from day 3 until day 6 
of cell culture in bacteriological cell culture plates on the shaker. Subsequently EBs were 
outgrown on cover slips in tissue culture plates and further treated with Silibinin until day 
14 of cell culture. Medium change was performed every day till day 14. 
1- Sample collection: On day 14, the EBs were removed from the incubator, the medium 
was aspirated and washed 3 times with 1x PBS to remove the medium. 
2- Fixation: The EBs were fixed in 4% PFA and incubated at +4ºC for 45 min.  
3- Blocking: After fixation, the EBs were washed 4 times with 0.01% PBST (Tween-20) 
buffer, 10% milk powder dissolved in 0.01% PBST (Tween-20) buffer was added, and EBs 
were further incubated for 1h at RT on the shaker. 
4- Primary Antibody: After blocking, EBs cells were washed 4 times with 0.01% PBST 
(Tween-20). The primary antibody (CD45, CD18 or CD68) diluted 1:100 in 10% milk was 
added and incubated overnight at +4°C. 
5- Secondary Antibody: The EBs were washed 4 times with 0.01% PBST (Tween-20) 
buffer and left for 10 min on the shaker with 0.01% PBST (Tween-20) buffer to ensure the 
removal of surplus primary antibody. The secondary antibody anti-rat Alexa 488 (dilution 
1:100) in 10% milk was added for 1h in the dark on the shaker at RT. Subsequently EBs 
were washed 4 times with 0.01% PBST (Tween-20).  
6- DRAQ5 staining: The EBs were washed with 1x PBS 3 times and stained with DRAQ5 
(1:1000) at RT for 20 min in dark for nuclear staining. Subsequently, the EBs were washed 
Materials and Methods 
 
44 
 
with 1x PBS buffer 3 times, the cover slips were mounted on object slides with 
Fluoromount-G and stored at +4°C till analysis. 
7- Imaging: EBs on objective slides were transferred to the stage of the Leica confocal 
microscope and leukocyte markers were assessed using a 20x immersion corrected 
objective. 
8- Analysis: Confocal images were collected from 15-20 EBs. The MetaMorph image 
analysis software was used to assess the number of leukocyte marker positive cells per total 
number of cells which were visualized by DRAQ5-labelled cell nuclei.  
 
2.4. Ca
2+
 measurement 
2.4.1. Isolation of cardiomyocytes, dissociation of cells and plating  
Intracellular Ca
2+
 was recorded in single cardiac contracting cells. Single cell preparations 
were obtained by enzymatic digestion of 7-day-old EBs for 30 min at 37°C in PBS 
containing 2mg/ml Collagenase B. Dissociated single cells were plated onto gelatin-coated 
cover slips in 24-well cell culture plates, and cultivated in Iscove’s medium supplemented 
with 16% FCS.  
2.4.2. Ca
2+
 detection (Fluo-4 fluorescence measurement) 
Following 24h of culture, cells were loaded in serum-free medium with 1µM Fluo-4-AM 
for 30 min. Subsequently, the cover slips were transferred in fresh serum-free cell culture 
medium to the incubation chamber of the confocal laser scanning microscope. Fluorescence 
excitation was performed at 488nm, emission was recorded at 500-550nm. For analysis of 
intracellular calcium a HCPL Apo 20x immersion corrected objective was used. Sampling 
rate was 2 frames/s. The fluorescence emission of single cells was assessed by using the 
image analysis software of the confocal setup. 
 
2.5. NO measurement 
For the measurement of NO the fluorescent NO indicator DAF-FM diacetate was dissolved 
in DMSO to achieve a stock solution of 5mM. On day 5 of differentiation EBs were treated 
with Silibinin and stained on day 6 with 5µM DAF-FM for 30 min in dark conditions on a 
shaker placed in an incubator (37°C and 5% CO2). Then the medium was replaced for 
serum-free medium and further incubated for 30 min in dark on the shaker. The 
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fluorescence of the sample was detected by confocal laser scanning microscopy (Leica SP2 
AOBS) with the argon laser (excitation 495nm), and emission was recorded at wavelength 
of 515nm. 
  
2.6. Western blot (immunoblotting) 
2.6.1. Protein extraction 
The total protein concentration was measured by the colorimetric Lowry method (Lowry et 
al., 1951) using a Tecan Infinite M200 Microplate reader instrument (Tecan Group Ltd., 
Männedorf, Switzerland).  
2.6.2. Gel electrophoresis 
To perform semi-quantitative western blot, 20µg aliquots of each protein sample were 
mixed with 1x NuPAGE LDS sample buffer and 1x NuPAGE reducing agent (Thermo 
Fisher Scientific, Darmstadt, Germany). The freshly prepared protein mixture was 
incubated for 10 min at 70
o
C for denaturation, and then was immediately loaded on a 4-
12% gradient PAGEr EX Precast polyacrylamide mini-Gel (Lonza, Rockland, USA). The 
gel electrophoresis was run at 200V for 45-55 min at RT. 
After gel electrophoresis, proteins were transferred from the SDS-PAGE gel onto PVDF 
membranes for 60 min at 375mA using Invitrogen semi-dry apparatus as explained in 
figure 2.5. Afterwards, the membranes were stained with a Ponceau-S solution (0.1% 
Ponceau-S in 1% acetic acid) to control transfer of proteins onto membrane.  
 
 
 
 
 
 
 Figure 2.5: Schematic representation of protein transfer from gel membrane to the 
PVDF membrane in the XCell SureLock
TM
 Mini-Cell Blot Module from Invitrogen, as 
sandwich layers.  
Anode (+) 
Cathode (-) 
Sponge layers 
Filter papers 
PVDF membrane 
Gel membrane 
Filter papers 
Sponge layers 
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2.6.3. Staining with antibody and detection 
Next, the PVDF membrane was washed 2-3 times with ddH2O until the Ponceau-S staining 
was completely disappeared from the membranes and then incubated with blocking buffer 
(5% non-fat milk powder in 0.1% TBS-Tween) for 1h at RT with gentle agitation to reduce 
unspecific antibody binding. The membranes were washed 2-3 times with TBS-Tween 
(0.1%) and incubated with primary antibodies, 1:1000 diluted in 5% BSA in 0.1% TBS-
Tween, for overnight at 4
o
C with gentle agitation. Then, the membranes were washed and 
incubated with appropriate HRP-conjugated secondary antibodies (1:1000 diluted in 5% 
BSA in 0.1% TBS-Tween) for 1h at RT with gentle agitation. Finally, the membranes were 
properly washed with TBS-Tween (0.1%), and the protein bands were detected using 
chemiluminescent substrates (1.25mM Luminol + 225µM Coumaric acid + 3mM H2O2 in 
100mM Tris buffer, pH 8.5). The emitted chemiluminescence was visualized and converted 
into a digital image using a PEQLAB Gel documentation system (VWR Part of Avantor, 
Erlangen, Germany) assisted with the Chemi-Capt 5000 software (Version 15.01a, Vilber 
Smart Imaging, Eberhardzell, Germany). Subsequently, a densitometric analysis was 
performed on these captured digital images using the free available Java software ImageJ 
(Version 1.46, Wayne Rasband, National Institute of Health, USA) (Schindelin et al., 
2012). This densitometric analysis was based on the intensity of each visualized protein 
band on the captured digital images. The final value of each target protein band was 
obtained after normalizing with their respective house-keeping protein band. For final 
protein expression/phosphorylation quantification, this final value of each treated samples 
was compared with the final value of untreated control sample.  
Stripping: For reprobing the same membrane with another set of target proteins, the 
membranes were 2-3 times washed with TBS-Tween (0.1%) and afterwards stripped using 
the Restore PLUS western blot Stripping Buffer from Thermo Fisher Scientific (Darmstadt, 
Germany). For stripping procedure, the membranes were incubated in the above mentioned 
stripping buffer for 20 min in dark at RT on the shaker with gentle agitation. Next, the 
membranes were rinsed in TBS-Tween (0.1%) buffer. To control the success of the 
stripping procedure, the membranes were incubated with the chemiluminescent substrates 
to confirm that the previous antibody staining was completely removed from the 
membranes. After this confirmation step, the membranes were 2-3 times washed with TBS-
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Tween (0.1%) and the reprobing procedure was started from the blocking step as described 
before. 
2.7. Statistical analysis 
For statistical analysis GraphPad InStat statistics software (GraphPad Software Inc. La 
Jolla, CA) was used. Data are given as mean values + standard deviation (SD), with n 
denoting the number of experiments performed with independent ES cell cultures. In each 
experiment
 
at least 20 culture objects were analyzed unless otherwise indicated. Student’s t 
test for unpaired data and one-way ANOVA was applied as appropriate for statistical 
analysis. A value of * P < 0.05 was considered to be significant; ** P < 0.01 (very 
significant) and *** P < 0.001 as a highly significant. 
 
2.8. Software 
1- Chemicapt 500 - Western blot imaging software, PEQLAB Biotechnologie, Version 
15.01a, Vilber Smart Imaging, Eberhardzell, Germany. 
2- GraphPad Instat - Statistical analysis software. GraphPad Software Inc. La Jolla, CA 
USA. 
3- Image J - Western blot analysis software, Version 1.46, Wayne Rasband, National 
Institute of Health, USA. 
4- Leica Application Suite Advanced Fluorescence Leica Microsystems, Wetzlar, 
Germany  
5- MetaMorph offline- Microscopy Automation & Image Analysis Software- Molecular 
Devices, Sunnyvale, CA, USA. 
6- Microsoft Office - Data documentation Microsoft, California, USA. 
7- Tecan Magellan™ -ELISA Software Tecan, Tecan Group Ltd., Männedorf, 
Switzerland. 
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3. Results 
3.1. Effect of Silibinin on cardiomyogenesis of ES cells 
3.1.1. Effect of Silibinin on contraction frequency and number of contracting foci 
To examine the effects of Silibinin on the differentiation of cardiomyocytes, EBs were 
treated from day 3 until day 10 with different concentrations of Silibinin (1µM, 10µM, 
20µM and 50µM). From day 7 until day 10, contraction frequency, the number of 
contracting foci and the number of contracting EBs were assessed. It was observed that 
Silibinin treatment dose-dependently decreased contraction frequency (figure 3.1), the 
number of contracting foci (figure 3.2) as well as the number of contracting EBs (figure 
3.3). 
 
 
 
Figure 3.1: Effect of Silibinin on contraction frequency of EBs. (A) Decrease of 
contraction frequency per min upon treatment of EBs with increasing concentrations of 
Silibinin. (B) Dose-dependent decrease in contraction frequency following treatment with 
different concentrations of Silibinin compared to the untreated control on day 10, the bar 
chart shows the means + SD of n = 4 experiments; *** P < 0.001.  
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3.1.2. Effect of Silibinin on the size of cardiac cell areas 
To investigate whether Silibinin affected the size of cardiomyocyte cell areas differentiated 
from mouse ES cells, 3-day-old EBs were treated for 7 days with different concentrations 
of Silibinin (1µM, 10µM, 20µM and 50µM). On day 10, EBs were immunostained with an 
antibody against α-actinin and the size of cardiac areas was determined by confocal laser 
scanning microscopy. It was observed that Silibinin treatment dose-dependently decreased 
the size of α-actinin positive cell areas in EBs (figure 3.4).  
  
 
 
 
 
 
 
 
 
 
Figure 3.2: Effect of Silibinin on the differentiation of contracting of cardiac foci. (A) 
Dose-dependent decrease of contracting foci number (% of untreated, day 7). (B) Dose-
dependent decrease of contracting foci number compared to the untreated control on day 
10, the bar chart shows the means + SD of n = 4 experiments; * P < 0.05, ** P < 0.01. 
 
Figure 3.3: Effect of Silibinin on the number of spontaneously contracting EBs. (A) 
Dose-dependent decrease of contracting EB number (% of untreated, day 7). (B) Dose-
dependent decrease of contracting EB number compared to the untreated control on day 10, 
the bar chart shows the means + SD of n = 4 experiments; * P < 0.05, ** P < 0.01. 
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Figure 3.4: Effect of Silibinin on the size of -actinin positive cell areas of 
cardiomyocytes derived from mouse ES cells. (A) Confocal images of representative 
EBs stained against α-actinin (green) to determine the size of the positive areas. The bar 
represents 300μm. (B) Quantification of the size of α-actinin positive areas on day 10, the 
bar chart shows the means + SD of n = 3 experiments; ** P < 0.01, *** P < 0.001. 
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3.2. Effect of Silibinin on angiotensin II- (Ang II) induced cardiomyogenesis of mouse 
ES cells 
Previous studies have shown that the vasoactive hormone Ang II is stimulating 
cardiomyogenesis of ES cells (Wu et al., 2013). Moreover, a recent study demonstrated that 
Silibinin may act as an AT1 receptor antagonist (Bahem et al., 2015). Since the data of the 
present study demonstrated that Silibinin decreased cardiomyogenesis of ES cells and the 
frequency of contractions, we investigated whether Silibinin would interfere with Ang II-
induced cardiomyogenesis, contraction frequency and Ca
2+
 oscillations. 
 
3.2.1. Effect of Silibinin and Ang II on contraction frequency and number of 
contracting foci 
To investigate whether the contraction frequency was affected by Silibinin and Ang II 
treatment, we calculated the frequency of contractions per min. Three-day-old EBs were 
treated for 11 days, (from day 3 to day 14 of differentiation) either with Silibinin (20µM) 
alone, with Ang II (1µM) alone or with a combination of Silibinin and Ang II. We found 
that the contraction frequency was significantly increased upon Ang II treatment compared 
to untreated (control), whereas Silibinin (20µM) alone significantly decreased contraction 
frequency. Pre-incubation with Silibinin abolished the increase in contraction frequency 
achieved with Ang II (figure 3.5). 
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To further characterize the effect of Silibinin on Ang II-mediated cardiomyogenesis of ES 
cells the number of contracting cardiac foci (figure 3.6) as well as the number of 
contracting EBs (figure 3.7) were counted from day 7 until day 14 of cell culture. We found 
that Ang II increased the number of contracting foci and EBs as compared to the untreated 
control, while Silibinin (20μM) alone exerted an inhibitory effect. Pre-treatment with 
Silibinin abolished the stimulation of cardiomyogenesis achieved with Ang II. 
 
 
 
 
 
Figure 3.5: Effect of Silibinin and Ang II on contraction frequency of EBs. (A) 
Contraction frequency per min of EBs after different times of cell culture (day 7 to day 14). 
EBs remained either untreated or were treated with Silibinin (20µM), Ang II (1µM) or with 
a combination of Silibinin and Ang II (from day 3 to day 14) (B) Effect of Silibinin 
treatment on Ang II-mediated stimulation of contraction frequency as evaluated on day 14 
of cell culture. Silibinin (20µM) reduced the contraction frequency on day 14, the bar chart 
shows the means + SD of n = 5 experiments; ** P < 0.01, significantly different to the 
untreated control, ### P < 0.001 significantly different to Ang II alone. 
 
Figure 3.6: Effect of Silibinin and Ang II on contracting cardiac foci number. (A) EBs 
were treated with Silibinin (20µM), Ang II (1µM) or with a combination of Silibinin and 
Ang II (from day 3 to day 14). (B) Number of contracting foci (% of untreated control, day 
14). Pre-treatment with Silibinin (20µM) abolished the stimulation of cardiomyogenesis 
achieved with Ang II, the bar chart shows the means + SD of n = 5 experiments; * P < 0.05 
significantly different to the untreated control, ### P < 0.001 significantly different to Ang 
II alone.  
 
 
0
50
100
150
200
250
300
350
C
o
n
tr
ac
ti
n
g
 f
o
ci
 n
o
.
(%
 o
f 
u
n
tr
ea
te
d
-d
ay
  
7
 )
Day 7 Day 8 Day 9 Day 10
Day 11 Day 12 Day 13 Day 14
0
50
100
150
200
250
C
o
n
tr
ac
ti
n
g
 f
o
ci
 n
o
.
(%
 o
f 
u
n
tr
ea
te
d
-d
ay
 1
4
)
###
*
-A- -B-
Sil 
Untreated 
Ang II 
Sil + Ang II
Results 
 
53 
 
 
 
 
 
 
3.2.2. Effect of Silibinin and Ang II on the size of contracting cardiac areas 
To examine the effect of Silibinin and Ang II on the size of cardiac areas, EBs remained 
untreated, were treated with Ang II (1µM) (from day 3 to day 14 of cell culture) alone or 
pre-incubated for 30 min with Silibinin (20µM) either in absence of presence of Ang II. 
Cardiac differentiation was investigated by assessing the size of α-actinin-positive cell 
areas at day 14 (figure 3.8). 
Silibinin alone significantly reduced the size of the α-actinin-positive areas compared to the 
untreated control, whereas a significant increase was observed upon Ang II treatment. Co-
treatment with Silibinin and Ang II abolished the stimulation of cardiomyogenesis achieved 
with Ang II. 
 
Figure 3.7: Effect of Silibinin and Ang II on spontaneously contracting EBs. (A) 
Number of contracting EBs (% of untreated day 7). EBs were treated with Sil (20µM), Ang 
II (1µM) and Sil + Ang II from (day 3 - 14), while the number of contracting EBs was 
calculated from (day 7 - 14). (B) Effect of Silibinin and Ang II on the number of 
contracting EBs (day 14). Silibinin treatment alone decreased the number of contracting 
EBs compared to untreated controls, whereas Ang II significantly increased the number of 
contracting EBs. The stimulation of contraction activity achieved with Ang II was 
abolished upon co-treatment with Silibinin, the bar chart shows the means + SD of n = 5 
experiments; * P < 0.05 significantly different to the untreated control, ## P < 0.01 
significantly different to Ang II alone. 
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3.3. Effect of Silibinin and Ang II on Ca
2+
 oscillations in cardiomyocytes 
Spontaneous contractions and action potentials in cardiac cells are associated to rhythmic 
Ca
2+
 oscillations. Since our data demonstrated that Ang II treatment stimulated 
cardiomyogenesis of ES cells, we investigated whether Ang II treatment would have an 
impact on cardiac cell function. To achieve this aim, contracting EBs (day 7 of cell culture) 
Untreated Sil 20µM Ang II  1µM Sil + Ang II
-A-
###** -actinin**
Figure 3.8: Effect of Silibinin and Ang II on the size of -actinin positive cardiac 
areas differentiated from mouse ES cells. (A) Representative α-actinin-positive cardiac 
areas (green) under the following experimental conditions (from the left to the right): 
untreated, Silibinin (20µM), Ang II (1µM), Sil + Ang II. The bar represents 300μm. (B) 
Quantification of the relative size of cardiac areas at day 14. The untreated control was set 
to 100%, the bar chart shows the means + SD of n = 4 experiments; ** P < 0.01 
significantly different to the untreated control, ### P < 0.001 significantly different to Ang 
II alone. 
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were enzymatically dissociated, labeled with the Ca
2+
-sensitive fluorescence dye Fluo-4- 
AM on day 8, and intracellular Ca
2+
 oscillations were recorded in single cardiac cells after 
different times of incubation (200 s, 600 s, 1500 s) with either Ang II (1µM), Silibinin 
(20µM) or a combination of both. It was evident that Silibinin treatment decreased the 
frequency of Ca
2+
 spikes which was significant after 1500 s of incubation. In contrast an 
increase in spiking frequency was observed upon Ang II treatment. However, when Ang II 
was applied after pre-incubation with Silibinin the stimulation of Ca
2+
 spiking frequency 
was abolished, which indicates that Silibinin interferes with Ang II-mediated signaling 
pathways (figure 3.9 A, B). 
 
 
 
 
 
 
 
Figure 3.9 A: Effects of Silibinin and Ang II on the frequency of Ca
2+ 
transients in 
cardiac cells differentiated from ES cells. Cardiac cells were enzymatically dissociated 
from 7-day-old EBs and labeled on day 8 with the Ca
2+-
sensitive fluorescence dye Fluo-4. 
Ca
2+ 
spiking was evaluated in 3 different time windows, i.e. 200 s, 600 s and 1500 s. 
Shown are representative traces of individual cells. (a) Untreated controls, (b) Silibinin 
(20μM) treated cells; (c) Ang II (1μM) treated cells, (d) cells treated with a combination of 
Silibinin (20μM) and Ang II (1μM). 
 
 
a
b
c
d
200 s 600 s 1500 s
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0
100
200
0 5 10 15 20 0 5 10 15 20 0 5 10 15 20
0 5 10 15 20 0 5 10 15 20 0 5 10 15 20
0 5 10 15 20 0 5 10 15 20 0 5 10 15 20
0 5 10 15 20 0 5 10 15 20 0 5 10 15 20
F
lu
o
-4
 f
lu
o
re
sc
e
n
c
e
 (
c
o
u
n
ts
)
Time (s)
-A-
Results 
 
56 
 
0
5
10
15
20
25
30
35
40
45
Untreated Silibinin Angiotensin II sil +Angiotensin II
N
o.
 o
f 
C
a2
+
 tr
an
si
en
ts
 p
er
 m
in
200s
600s
1500s
*
***
###
ntreated il 20µM Ang II 1µM Sil + Ang II 
600 s
2 0 s
15 0 s
-B-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Effects of Silibinin and Ang II on the function of adult rat cardiomyocytes 
Since cardiomyocytes differentiated from ES cells may be immature and represent a fetal 
phenotype, we investigated whether Silibinin would interfere with Ang II-mediated 
changes in cardiac cells isolated from the ventricles of adult rat hearts. To achieve this aim, 
the protocol developed by Mufti et al., 2008 was applied. Our data demonstrated that after 
24h incubation with Ang II (10µM) a significant decrease in contraction as well as 
relaxation velocity occurred. Moreover, Ang II significantly reduced the contraction 
velocity indicated by diastolic cell lengths of individual cells (dL/L) and decreased the time 
to reach 50% of peak contraction (TTP50). Treatment with Silibinin alone (20µM) was 
without effect. Upon co-incubation of Ang II with Silibinin for 24h, the effects observed 
with Ang II alone were totally abolished (figure 3.10 A, B, C and D). 
 
 
 
Figure 3.9 B: Bar chart of Silibinin and Ang II effects on the frequency of Ca
2+
 
transients. The bar chart shows the means + SD of 10 experiments and indicates, that Ang 
II increased the Ca
2+
 spiking frequency which was completely reversed upon co-treatment 
with Silibinin. * P < 0.05, significantly different to the untreated control. *** P < 0.001, 
significantly different to Silibinin, ### P < 0.001, significantly different to the Ang II 
treated sample. 
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Figure 3.10 A-D: The effect of Silibinin and Ang II on cardiac cell function. (A) 
Isolated rat cardiomyocytes were incubated for 24h with either Silibinin (Sil) (20µM) 
alone, Ang II (10µM) alone or a combationation of both, and contraction velocity was 
investigated. Ang II caused significant decrease in contraction velocity compared to the 
untreated control which was reversed upon co-treatment with Silibinin. (B) Effect of 
Silibinin and Ang II on relaxation velocity. Ang II (10µM) caused significant decrease in 
relaxation velocity which was reversed upon co-treatment with Silibinin. (C) Effect of 
Silibinin and Ang II on changes in diastolic cell lengths (dL/L (%)). The observed decrease 
in diastolic cell lengths was reversed upon co-treatment with Silibinin. (D) Effect of 
Silibinin and Ang II on R50-TTP 50. The decrease in R50-TTP 50 observed with Ang II 
was reversed upon co-treatment with Silibinin. n = 4 experiments; * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
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3.5. Inhibition of Ang II-mediated extracellular signal-regulated kinase 1/2 (ERK1/2), 
p38 and c-Jun N-terminal kinase (JNK) phosphorylation by Silibinin  
Previous data of our group (unpublished data) on adult rat smooth muscle cells 
demonstrated that Silibinin could not blunt the Ang II-induced Ca
2+
 response, thus ruling 
out that Silibinin acted on the AT1 receptor. We therefore assumed that Silibinin may 
interfere with downstream signaling cascades. Since it has been previously shown that Ang 
II activates ERK1/2, p38 and JNK in differentiating ES cells (Wu et al., 2013), we 
investigated whether Silibinin (20μM) would abolish MAPK activation upon treatment of 
EBs with Ang II (1μM). Indeed, Silibinin treatment of 6-day-old EBs efficiently abolished 
the Ang II-mediated activation of ERK1/2, p38 and JNK (figure 3.11) as evaluated using 
phospho-specific antibodies. These data corroborated our assumption that Silibinin 
interfered with Ang II signaling downstream of the AT1 receptor. 
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3.6. Stimulation of vasculogenesis in differentiating mouse ES cells upon Silibinin 
treatment 
Cardiac and vascular cells are known to originate from a common cardiovascular 
progenitor cell (Ishida et al., 2012). We therefore investigated whether Silibinin would 
affect vasculogenesis from ES cells. To address this point, EBs were incubated from day 3 
to day 10 of differentiation with increasing concentrations of Silibinin, ranging from 1 - 
50μM. At day 10 the EBs were collected, fixed and stained against the endothelial marker 
CD31/ PECAM-1 which is expressed at the intercellular junctions of endothelial cells. 
Vascular branching points were assessed by confocal laser microscopy and computer-
assisted image analysis (figure 3.12). Silibinin treatment resulted in a dose-dependent 
increase of branching points with maximum effects achieved with 10µM, whereas higher 
concentrations (20 - 50µM) exerted adverse effects.  
 
 
 
 
 
 
Figure 3.11: Effects of Silibinin and Ang II on MAP kinase (ERK1/2, p38 and JNK) 
phosphorylation. 6-day-old EBs remained either untreated or were treated with Ang II 
(1µM), Silibinin (20µM) or a combination of both. MAPK activation was monitored after 
15 min of incubation with Ang II by western blot analysis using phospho-specific 
antibodies. Vinculin was used as house-keeping protein. In (A) representative western blots 
are shown. Upper panel ERK1/2 (42-44 kDa), middle panel p-p38 (43 kDa), bottom panel 
p-JNK (46 kDa, phospho-JNK1; 54 kDa, phospho-JNK2/3). The bar in (B) charts show the 
means + SD of (n = 6) experiments for ERK1/2 and (n = 5) experiments for p38 and JNK, 
respectively. Note that Silibinin pre-treatment completely abolished MAPK activation 
achieved with Ang II. * P < 0.05, ** P < 0.01, significantly different to the untreated 
control. ### P < 0.001, significantly different to the Ang II treated sample. 
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Figure 3.12: Effect of increasing concentrations of Silibinin on vascular branch 
formation. (A) Representative images of EBs treated with different concentrations of 
Silibinin or vehicle and stained against CD31 at day 10. CD31 staining (red), DRAQ5-
positive cell nuclei (green). The bar represents 300μm. (B) The bar chart shows the means 
+ SD of n = 5 experiments as percentage values. (25 - 30 EBs were analyzed in each 
experiment), * P < 0.05, *** P < 0.001. 
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3.7. Expression of angiogenesis-related proteins upon Silibinin treatment 
To assess whether the increased branching of vascular structures achieved with Silibinin 
was associated to pro-angiogenic proteins, the expression of VEGFR2 (FLK-1), VE-
Cadherin and HIF-1 was investigated. 3-day-old EBs were treated with different 
concentrations of Silibinin for 7 days. On day 10, EBs were collected for determination of 
protein expression (figure 3.13). Silibinin treatment induced protein expression for 
VEGFR2, HIF-1 and VE-Cadherin which was significant at 10µM. 
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Figure 3.13: Induction of VEGFR2, HIF-1  and VE-Cadherin expression upon 
Silibinin treatment. (A) Representative western blots of protein expression in EBs treated 
with different concentrations of Silibinin. (B) Graphical representation of protein 
expression upon treatment with different concentrations of Silibinin, the bar chart shows 
the means + SD of (n = 5 experiments) for VEGFR2, HIF-1 (n = 6) and VE-Cadherin (n 
= 5). -actin was used as house-keeping protein, * P < 0.05, significantly different to the 
untreated control. 
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3.8. Generation of NO upon Silibinin treatment of EBs  
NO plays important roles in vascular biology and pathology (Walford and Loscalzo, 2003). 
Notably NO has been previously shown to regulate processes of vasculogenesis of EB cells 
(Sauer et al., 2013; Sharifpanah et al., 2016). Therefore, it was investigated whether 
Silibinin treatment would stimulate NO generation in EBs. To achieve this aim, 5-day-old 
EBs were treated with different doses of Silibinin (1µM, 10µM, 20µM and 50µM). After 
24h (day 6), the EBs were incubated with the fluorescent NO indicator DAF-FM and DAF 
fluorescence was recorded. It was observed that Silibinin in concentrations of 1µM and 
10µM significantly increased NO generation, whereas higher concentrations (20µM and 
50µM) exerted adverse effects (figure 3.14). 
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3.9. Enhancement of eNOS phosphorylation upon Silibinin treatment of EBs 
In the vascular system, the main NOS isoform is eNOS / NOS III (Shaul, 2002; Liu and 
Huang, 2008). Therefore, eNOS phosphorylation was assessed following 5, 10, 15, 30, 60 
and 120 min pre-incubation with Silibinin (10µM) by western blot assays in 6-day-old EBs. 
Our data showed that eNOS phosphorylation was significantly up-regulated within 30 min 
after Silibinin treatment compared to the untreated control (figure 3.15). 
 
Figure 3.14: Effect of Silibinin on NO generation of EBs. (A) NO generation upon 
treatment of EBs (6-day-old) with different concentrations (1-50µM) of Silibinin. Silibinin 
significantly induced NO generation at concentrations of 1µM and10µM compared to the 
untreated control. NO production was assessed by use of the fluorescence dye DAF-FM. 
The bar represents 300µm. (B) Graphical representation of NO generation at different 
doses of Silibinin. Shown are the means + SD of n = 4 experiments with 20 EBs in each 
experiment, * P < 0.05, ** P < 0.01. 
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3.10. Inhibition of eNOS by L-NAME 
3.10.1. Effect of the eNOS inhibitor L-NAME on Silibinin-induced NO generation 
To confirm that NO was generated through eNOS, 5-day-old EBs were treated either with 
the NOS inhibitor L-NAME (100µM) alone, with Silibinin (10µM) alone or with a 
combination of both, and compared with untreated controls. NO was assessed using the NO 
indicator DAF-FM. Upon L-NAME treatment NO generation upon Silibinin treatment was 
completely abolished, indicating that NO production was due to stimulation of eNOS by 
Silibinin (figure 3.16). 
 
 
Figure 3.15: Phosphorylation of eNOS upon treatment of EBs with Silibinin (10µM). 
(A) Representative western blot using a phospho eNOS-specific antibody. GAPDH was 
used as house-keeping protein. The bar chart in (B) shows the means + SD of n = 5 
experiments for eNOS phosphorylation to GAPDH and eNOS phosphorylation to total 
eNOS. * P < 0.05, ** P < 0.01, # P < 0.05, ## P < 0.01. 
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3.10.2. Effect of the eNOS inhibitor L-NAME on Silibinin-induced eNOS 
phosphorylation 
The effect of L-NAME on NO generation may be due to inhibition of eNOS 
phosphorylation. To address this point 6-day-old EBs were pre-treated for 2h with L-
NAME (100µM) and subsequently with Silibinin (10µM). It was apparent that the 
Silibinin-induced eNOS phosphorylation was completely abolished in the presence of L-
NAME. Notably, L-NAME treatment alone decreased eNOS activity below the control 
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Figure 3.16: Inhibition of Silibinin-induced NO generation by the NOS inhibitor L-
NAME (100µM). (A) Confocal images show representative EBs displaying DAF 
fluorescence. The bar represents 300µm. The bar chart in (B) shows the means + SD of n = 
5 experiments. *** P < 0.001 significantly different to the untreated control, ### P < 0.001 
significantly different to Silibinin alone.  
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value, indicating that NO generation occurs in EBs during cardiovascular differentiation 
processes (figure 3.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.10.3. Effect of the eNOS inhibitor L-NAME on Silibinin-induced vasculogenesis of 
mouse ES cells  
The data of the present study demonstrate that Silibinin efficiently raises NO in EBs 
through activation of eNOS. Since vasculogenesis is well known to require NO generation 
(Milosevic et al., 2010), 3-day-old EBs were treated until day 10 of cell culture every 24h 
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Figure 3.17: Blocking of Silibinin-induced eNOS phosphorylation by the NOS 
inhibitor L-NAME. (A) Western blot analysis of eNOS phosphorylation which was 
detected by using an anti p-eNOS (ser1177) antibody. GAPDH was used as house-keeping 
protein. L-NAME (100µM) completely blocked eNOS phosphorylation compared to the 
untreated control as well as in the Silibinin-treated sample (B) The bar chart shows the 
means + SD of n = 4 experiments * P < 0.05, ** P < 0.01 significantly different to the 
untreated control, ### P < 0.001 significantly different to Silibinin alone.  
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with Silibinin (10µM), L-NAME (100µM) or a combination of Silibinin with L-NAME. At 
day 10, EBs were fixed, staining against CD31 antibody and analyzed by confocal laser 
microscopy. L-NAME significantly decreased branching points in the absence of Silibinin 
compared to the untreated control and abolished the stimulation of vasculogenesis achieved 
upon Silibinin treatment, thus supporting the notion that Silibinin-stimulated 
vasculogenesis by elevating intracellular NO levels (figure 3.18). 
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Figure 3.18: Inhibition of Silibinin-induced vasculogenesis upon NOS inhibition by L-
NAME. (A) The increase in branching points observed upon Silibinin (10µM) treatment 
was completely abolished in the presence of L-NAME (100µM). Shown are representative 
EBs treated from day 3 to day 10 of differentiation. CD31 staining (red), DRAQ5-positive 
cell nuclei (green). The bar represents 300µm. (B) Bar chart showing the means + SD of n 
= 5 experiments * P < 0.05, ** P < 0.01 significantly different to the untreated control, ### 
P < 0.001 significantly different to Silibinin alone.  
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3.10.4. Effect of the NOS inhibitor L-NAME on Silibinin-stimulated VEGFR2 and 
VE-Cadherin expression 
The data of the present study demonstrate that L-NAME inhibited branching point 
formation (see 3.10.3). To investigate whether L-NAME would affect the expression of 
VEGFR2 and VE-Cadherin, EBs were treated from day 3 to day 10 of differentiation with 
Silibinin (10µM) either in presence or absence L-NAME (100µM). At day 10, EBs were 
collected and protein extraction was performed. As expected Silibinin-stimulated 
expression of the endothelial cell progenitor marker VEGFR2 and the endothelial marker 
VE-Cadherin, while the observed effect was completely abolished by L-NAME (figure 
3.19). 
 
 
 
 
 
 
Figure 3.19: Inhibition of VEGFR2 and VE-Cadherin by L-NAME upon Silibinin 
treatment. (A) Representative western blot for VEGFR2 and VE-Cadherin. -actin was 
used as house-keeping protein. At day 10, protein extraction and western blot analysis were 
performed. Silibinin significantly increased the expression of VEGFR2 and VE-Cadherin. 
Moreover, pre-treatment with L-NAME (100µM) decreased VEGFR2 and VE-Cadherin 
expression. (B) The bar chart shows the means + SD of n = 4 experiments; ** P < 0.01 
significantly different to the untreated control, # P < 0.05, ## P < 0.01 significantly 
different to Silibinin alone.  
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3.11. Induction of STAT3, AKT, PI3K and VEGFR2 phosphorylation upon treatment 
of EBs with Silibinin 
To examine, whether Silibinin could regulate STAT3, PI3K/AKT and VEGFR2 activation, 
6-day-old differentiating EBs were treated with 10µM Silibinin and STAT3, AKT, PI3K 
and VEGFR2 phosphorylation was analyzed using phospho-specific antibodies. 6-day-old 
differentiating EBs were treated with Silibinin (10µM), collected at 5, 10, 15, 30, 60 and 
120 min and analyzed by western blot technique (figure 3.20). Indeed Silibinin (10µM) 
transiently increased the phosphorylation of STAT3, AKT and PI3K following 5 - 10 min 
of treatment. The activation remained on an elevated plateau for more than 30 min and 
reached control values approximately 60 min after Silibinin application. Significant 
activation of VEGFR2 was observed following 30 min of Silibinin treatment.  
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3.12. Effect of pharmacological inhibitors on STAT3, AKT and PI3K activation upon 
Silibinin treatment of EBs 
The data of the present study show that Silibinin treatment activates angiogenesis-related 
signalling pathways, e.g. STAT3, AKT or PI3K. These protein kinases may be activated 
independently or may interfere in a common signal transduction cascade. We therefore 
applied specific pharmacological inhibitors, i.e. the PI3K inhibitor LY294002 (5µM), the 
STAT3 inhibitor Stattic (7µM), or the AKT inhibitor AKT inhibitor VIII (5µM) and 
assessed activation of PI3K (figure 3.21), STAT3 (figure 3.22), or AKT (figure 3.23). Our 
Figure 3.20: Phosphorylation of STAT3, AKT, PI3K and VEGFR2 upon Silibinin 
treatment. (A) Representative western blots for activation of phospho-STAT3 (ser727), 
phospho-AKT (ser473), phospho-PI3K and phospho-VEGFR2. GAPDH was used as 
house-keeping protein. Silibinin treatment of EBs was performed on day 6 of cell 
differentiation. (B) The bar chart shows the means + SD of n = 4 experiments for phospho-
STAT3, n = 5 experiments and n = 4 experiments for phospho-AKT and phospho-PI3K 
respectively, and n = 5 experiments for phospho-VEGFR2. * P < 0.05, ** P < 0.01 
significantly different to the untreated control. 
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data demonstrated that the PI3K inhibitor LY294002 abolished the activation of PI3K, 
STAT3 and AKT. Upon co-treatment of Silibinin with Stattic, activation of STAT3 and 
AKT was inhibited. Treatment with Silibinin in presence of AKT inhibitor VIII inhibited 
AKT as well as STAT3 phosphorylation. Taken together these data demonstrate that 
Silibinin activates PI3K, STAT3 and AKT in the same signal transduction cascade. 
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Figure 3.21: Effect of PI3K inhibitor LY294002 on Silibinin-mediated PI3K 
phosphorylation. (A) Representative western blots showing PI3K activation by use of a 
phospho-specific anti-PI3K antibody in the presence or absence of PI3K inhibitor 
LY294002 (5µM). -actin was used as house-keeping protein. (B) The bar chart shows the 
means + SD of n = 6 experiments for LY294002. * P < 0.05, ** P < 0.01 significantly 
different to the untreated control, # P < 0.05 significantly different to Silibinin alone.  
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Figure 3.22: Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT VIII and PI3K 
inhibitor LY294002 on Silibinin-mediated STAT3 phosphorylation. (A) Representative 
western blots showing STAT3 activation by use of a phospho-specific anti-STAT3 
antibody in the presence or absence of either STAT3 inhibitor Stattic (7µM) (upper panel), 
AKT inhibitor VIII (5µM) (middle panel) or PI3K inhibitor LY294002 (5µM) (lower 
panel). GAPDH and -actin were used as house-keeping proteins. (B) Bar chart showing 
the means + SD of n = 4 experiments for Stattic (red bars), n = 5 experiments for AKT 
inhibitor VIII (blue bars), and n = 5 experiments for LY294002 (green bars). * P < 0.05, ** 
P < 0.01, *** P < 0.001 significantly different to the untreated control, # P < 0.05, ## P < 
0.01 significantly different to Silibinin alone.  
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Figure 3.23: Effect of AKT inhibitor AKT VIII, STAT3 inhibitor Stattic and PI3K 
inhibitor LY294002 on Silibinin-mediated AKT phosphorylation. (A) Representative 
western blots showing AKT activation by use of a phospho-specific anti-AKT antibody in 
the presence or absence of either AKT inhibitor VIII (5µM) (upper panel), STAT3 inhibitor 
Stattic (7µM) (middle panel) or PI3K inhibitor LY294002 (5µM) (lower panel). -actin 
was used as house-keeping protein. (B) The bar chart shows the means + SD of n = 5 
experiments for AKT inhibitor VIII (red bars), n = 4 experiments for Stattic (blue bars) and 
n = 6 experiments for LY294002 (green bars). * P < 0.05, *** P < 0.001 significantly 
different to the untreated control, # P < 0.05, ### P < 0.001 significantly different to 
Silibinin alone. 
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3.13. Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and PI3K 
inhibitor LY294002 on Silibinin-mediated NO generation 
To interpret the potential involvement of Stattic, AKT inhibitor VIII and LY294002 in 
Silibinin-induced NO generation of mouse ES cells, 6-day-old EBs were assessed for NO 
generation by utilizing the NO-sensitive fluorescence indicator DAF-FM (1µM). 
Generation of NO in EBs increased upon Silibinin (10μM) treatment, Stattic (7µM), AKT 
inhibitor (5µM) and LY294002 (5µM) treatment strongly inhibited NO production (figure 
3.24). These results indicate that the NO production following Silibinin treatment is 
occurring downstream of the STAT3 and PI3K/AKT signaling pathways. 
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3.14. Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and PI3K 
inhibitor LY294002 on Silibinin-induced eNOS activation 
To explain whether the signaling cascade elicited upon Silibinin treatment affected the 
activity of eNOS, the effects of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII 
and PI3K inhibitor LY294002 on the phosphorylation of eNOS was investigated. 6-day-old 
EBs were treated with Silibinin (10µM) for 30 min in absence and presence of Stattic 
(7µM), AKT inhibitor AKT inhibitor VIII (5μM) and PI3K inhibitor LY294002 (5μM) 
(figure 3.25). It was shown that inhibition of STAT3 and PI3K/AKT significantly inhibited 
the phosphorylation achieved with Silibinin, thus corroborating the data on NO generation 
and suggesting that NO was generated by eNOS. 
Figure 3.24: Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and 
PI3K inhibitor LY294002 on Silibinin-mediated NO generation. (A) Representative 6-
day-old DAF stained EBs which either remained untreated or were treated with Silibinin 
(Sil) in the absence or presence of either STAT3 inhibitor Stattic (7μM), AKT inhibitor 
AKT inhibitor VIII (5μM) or PI3K inhibitor LY294002 (5μM). EBs were stained with 
fluorescence indicator DAF-FM and the elevation DAF fluorescence was assessed. The bar 
represents 300µm. (B) The bar chart represents the means + SD of n = 4 experiments for 
Stattic (red bars), n = 4 experiments for AKT inhibitor (blue bars) and n = 5 experiments 
for LY294002 (green bars), ** P < 0.01, *** P < 0.001 significantly different to the 
untreated control, ### P < 0.001 significantly different to Silibinin alone. 
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3.15. Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and PI3K 
inhibitor LY294002 on Silibinin-induced vasculogenesis  
Differentiation of mouse ES cells to vascular-like structures positive for the vascular 
marker CD31/PECAM-1 occurs within 10 days (Wartenberg et al., 2006). To unravel 
participation of STAT3, AKT and PI3K in vasculogenesis initiated by Silibinin, EBs were 
treated for 7 days, i.e. from day 3 to day 10 of cell culture with Silibinin (10µM) alone in 
the absence or presence of Stattic (7µM), AKT inhibitor VIII (5µM) or LY294002 (5µM). 
Silibinin treatment resulted in a significant increase in vascular-like structures as compared 
to the untreated control, which was totally abrogated upon Stattic, AKT inhibitor VIII and 
LY294002 treatment (figure 3.26). 
Figure 3.25: Inhibition of Silibinin-induced eNOS activation by STAT3 inhibitor 
Stattic, AKT inhibitor AKT inhibitor VIII and PI3K inhibitor LY294002 (A) 
Representative western blots of 6-day-old EBs showing eNOS activation by use of a 
phospho-specific anti-eNOS antibody in the presence or absence of either STAT3 inhibitor 
Stattic (7µM) (upper panel), AKT inhibitor VIII (5µM) (middle panel) or PI3K inhibitor 
LY294002 (5µM) (lower panel). -actin was used as house-keeping protein. (B) Bar chart 
showing the means + SD of n = 4 experiments for Stattic (red bars), n = 5 experiments for 
AKT inhibitor VIII (blue bars) and n = 5 experiments for LY294002 (green bars). * P < 
0.05, ** P < 0.01, *** P < 0.001 significantly different to the untreated control, # P < 0.05, 
## P ≤ 0.01, ### P ≤ 0.001 significantly different to Silibinin alone.  
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3.16. Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and PI3K 
inhibitor LY294002 on vasculogenic protein expression 
Vasculogenesis is regulated in ES cells by activation of VEGFR2 and the transcription 
factor HIF-1α (Koch and Claesson-Welsh, 2012; Zimna and Kurpisz, 2015). To investigate, 
whether the signaling pathways identified in the present study to regulate vascular structure 
formation by Silibinin, affected vasculogenic protein expression, we treated differentiating 
EBs either with STAT3 inhibitor Stattic (7µM), AKT inhibitor AKT inhibitor VIII (5µM) 
or PI3K inhibitor LY294002 (5µM) and investigated VEGFR2 (figure 3.27) as well as HIF-
1α (figure 3.28) expression. In additional experiments we investigated VE-Cadherin 
expression (figure 3.29), which is an endothelium-specific protein required for proper 
vasculogenesis (Gory-Fauré et al., 1999). Indeed the data of the present study clearly 
demonstrate that inhibition of STAT3 and PI3K/AKT abolished the stimulation of 
VEGFR2, HIF-1α as well as VE-Cadherin expression by Silibinin. Taken together these 
data corroborate our previous data on a stimulation of vasculogenesis by Silibinin and 
demonstrate that basic vasculogenic signaling pathways via VEGFR2 and HIF-1α are 
involved in this process.  
 
 
Figure 3.26: Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and 
PI3K inhibitor LY294002 on Silibinin-induced vascular-like structures. (A) 
Representative EBs differentiated for 10 days with treatments as indicated. On day 10, EBs 
were collected fixed, stained against endothelial marker CD31/PECAM-1 and examined by 
confocal microscopy. CD31 staining (red), DRAQ5-positive cell nuclei (green). Silibinin 
treatment significantly increased the number of branching points which was completely 
reversed by Stattic (7µM), AKT inhibitor VIII (5µM) and LY294002 (5µM). The bar 
represents 300µm. (B) Graphic representation of the effects of Stattic, AKT inhibitor VIII 
and LY294002. The bar chart shows the means + SD for n = 5 experiments Stattic (red 
bars), n = 4 experiments AKT inhibitor VIII (blue bars) and n = 5 experiments LY294002 
(green bars). ** P < 0.01, *** P < 0.001 significantly different to the untreated control, ## 
P < 0.01, ### P < 0.001 significantly different to Silibinin alone. 
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Figure 3.27: Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and 
PI3K inhibitor LY294002 on Silibinin-induced VEGFR2 expression. (A) 
Representative western blots for VEGFR2. EBs were treated from day 3-10 with Silibinin 
(10µM), in the absence or presence of either Stattic (7µM) (upper panel), AKT inhibitor 
VIII (5µM) (middle panel) and LY294002 (5µM) (lower panel). -actin was used as house-
keeping protein. (B) The bar chart shows the means + SD of n = 4 experiments for Stattic 
(red bars), n = 4 experiments for AKT inhibitor VIII (blue bars) and n= 6 experiments for 
LY294002 (green bars). * P < 0.05, ** P < 0.01, *** P < 0.001 significantly different to the 
untreated control, # P < 0.05, ### P < 0.001 significantly different to Silibinin alone and ns 
(non-significant), P > 0.05. 
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Figure 3.28: Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and 
PI3K inhibitor LY294002 on Silibinin-induced HIF-1 expression. (A) Representative 
western blots for HIF-1. EBs were treated from day 3-10 with Silibinin (10µM), in the 
absence or presence of either Stattic (7µM) (upper panel), AKT inhibitor VIII (5µM) 
(middle panel) or LY294002 (5µM) (lower panel). -actin was used as house-keeping 
protein. (B) The bar chart show the means + SD of n = 4 experiments for Stattic (red bars), 
n = 4 experiments for AKT inhibitor VIII (blue bars) and n = 6 experiments for LY294002 
(green bars). * P < 0.05, ** P < 0.01, significantly different to the untreated control, # P < 
0.05, ## P < 0.01, ### P < 0.001, significantly different to Silibinin alone and ns (non-
significant), P > 0.05. 
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Figure 3.29: Effect of STAT3 inhibitor Stattic, AKT inhibitor AKT inhibitor VIII and 
PI3K inhibitor LY294002 on Silibinin-induced VE-Cadherin expression. (A) 
Representative western blots for VE-Cadherin expression. EBs were treated from day 3-10 
with Silibinin (10µM), in the absence or presence of either Stattic (7µM) (upper panel), 
AKT inhibitor VIII (5µM) (middle panel) or LY294002 (5µM) (lower panel). -actin was 
used as house-keeping protein. (B) The bar chart shows the means + SD of n = 4 
experiments for Stattic (red bars), n = 4 experiments for AKT inhibitor VIII (blue bars) and 
n = 6 experiments for LY294002 (green bars). * P < 0.05, *** P < 0.001 significantly 
different to the untreated control, # P < 0.05, ## P < 0.01, ### P < 0.001 significantly 
different to Silibinin alone.  
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3.17. Stimulation of leukocyte differentiation upon Silibinin treatment 
Previous studies demonstrated that leukopoiesis is closely associated to vasculogensis of 
mouse ES cells (Sharifpanah et al., 2015). Our data (shown in 3.6) have demonstrated that 
Silibinin stimulates vasculogenesis in mouse ES cells, therefore we investigated whether 
Silibinin would likewise induce leukocyte differentiation, EBs were treated from day 3 to 
day 14 with increasing doses of Silibinin (1µM, 10µM, 20µM and 50µM). On day 14 the 
expression of the leukocyte marker CD45, the leukocyte integrin marker CD18 and the 
macrophage marker CD68 (Suga et al., 2014; Hutterer et al., 2015; Kaser-Eichberger et al., 
2016) were assessed by immunohistochemistry. Maximum effects were achieved with 
10µM Silibinin which increased the number of CD45
+
, CD18
+
 and CD68
+
 cells per total 
cells from 8 + 1 % to 14 + 2 %, 9 + 1 % to 14 + 1 % and 11 + 2 to 20 + 6 %, respectively 
(figure 3.30 A, B, C and D). Taken together these results demonstrate that Silibinin not 
only increased vasculogenesis and NO generation but also up-regulated leukocyte 
differentiation of ES cells. 
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3.18. Expression of leukocyte proteins upon Silibinin treatment 
To confirm the observation that Silibinin increased the cell number of CD45
+
, CD18
+
 and 
CD68
+
 cells, western blot experiments were performed to assess protein expression of CD 
markers. 3-day-old EBs were treated with different concentrations of Silibinin for 11 days. 
On day 14, EBs were collected for determination of protein expression (figure 3.31). Our 
data demonstrated that Silibinin treatment dose-dependently increased protein expression 
for CD45, CD18 and CD68 which was significant at a concentration of 10µM. 
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Figure 3.30 A-D: Effect of Silibinin on leukocyte differentiation of mouse ES cells. 
Immunohistochemical analysis of the number of CD45
+
, CD18
+
 and CD68
+
 cells 
differentiated in ES cell derived EBs following treatment with Silibinin. (A-C) 
Representative images of outgrown EBs which were treated from day 3 to day 14 with 
Silibinin (1µM, 10µM, 20µM and 50µM) and subsequently labeled with antibodies against 
the leukocyte markers (A) CD45, (B) CD18 and (C) CD68 (upper panel, green). Total cells 
were labeled with DRAQ5 (middle panel, red). The lower panel shows overlay images of 
CD marker-positive and DRAQ5-labelled cells. The bar represents 75µm. (D) Quantitative 
analysis of the number of cells positive for CD45 (red bars, n = 4), CD18 (blue bars, n = 4) 
and CD68 (green bars, n = 3) in relation to the total (DRAQ5-positive) cell number (%) 
upon treatment with different concentrations of Silibinin.* P < 0.05, ** P < 0.01 
significantly different to the untreated control.  
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Figure 3.31: Increase of CD45, CD18 and CD68 expression upon Silibinin treatment. 
(A) Representative western blots of protein expression in EBs treated with different 
concentrations of Silibinin (B) Graphical representation of protein expression for CD45, 
CD18 and CD68 upon treatment with different concentrations of Silibinin. The bar chart 
shows the means + SD of (n = 4 experiments). -actin was used as house-keeping protein; 
* P < 0.05, ** P < 0.01, significantly different to the untreated control. 
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3.19. Effect of the eNOS inhibitor L-NAME, Stattic, AKT inhibitor VIII and 
LY294002 on leukocyte differentiation upon Silibinin treatment of mouse ES cells 
Our previous results demonstrated that Silibinin increased vasculogenesis. The stimulation 
of vasculogenesis was abolished upon inhibition of NOS, STAT3 and PI3K/AKT. Since 
vasculogenesis and leukopoiesis are regulated by comparable signaling pathways, it was 
investigated, whether L-NAME, Stattic, AKT inhibitor VIII and LY294002 would affect 
leukocyte differentiation upon Silibinin treatment. To achieve this aim, EBs were treated 
from day 3 to day 14 with Silibinin (10µM) either in the absence or presence of L-NAME 
(100µM), Stattic (7µM), AKT inhibitor VIII (5µM) and LY294002 (5µM), and western 
blot analysis for CD45, CD18 and CD68 was performed. Our results showed that L-
NAME, Stattic, AKT inhibitor VIII and LY294002, decreased protein expression of the 
leukocyte markers CD45 (figure 3.32), CD18 (figure 3.33) and the macrophage marker 
CD68 (figure 3.34) even in the absence of Silibinin. Moreover, the stimulation of leukocyte 
marker expression achieved upon Silibinin treatment was completely abolished. 
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Figure 3.32: Effect of L-NAME, Stattic, AKT inhibitor VIII and LY294002 on CD45 
expression upon Silibinin treatment of EBs. (A) Representative western blots showing 
CD45 expression either in the absence (untreated) or presence of Silibinin with or without 
inhibitors. -actin was used as house-keeping protein. (B) Graphic representation of 
western blots showing the means + SD of n = 4 experiments for L-NAME (red bars), 
Stattic (blue bars), AKT inhibitor VIII (green bars) and n = 3 experiments for LY294002 
(pink bars). * P < 0.05, ** P < 0.01, *** P < 0.001 significantly different to the untreated 
control, # P < 0.05, ## P < 0.01, ### P ≤ 0.001 significantly different to Silibinin alone and 
ns (non-significant), P > 0.05. 
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Figure 3.33: Effect of L-NAME, Stattic, AKT inhibitor VIII and LY294002 on CD18 
expression upon Silibinin treatment of EBs. (A) Representative western blots showing 
CD18 expression either in the absence (untreated) or presence of Silibinin with or without 
inhibitors. -actin was used as house-keeping protein (B) Graphic representation of western 
blots showing the means + SD of n= 4 experiments for L-NAME (red bars), Stattic (blue 
bars), AKT inhibitor VIII (green bars) and n = 3 experiments for LY294002 (pink bars). * 
P < 0.05, ** P < 0.01, *** P < 0.001 significantly different to the untreated control, ## P < 
0.01, ### P < 0.001 significantly different to Silibinin alone.  
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Figure 3.34: Effect of L-NAME, Stattic, AKT inhibitor VIII and LY294002 on CD68 
expression upon Silibinin treatment of EBs. (A) Representative western blots showing 
CD68 expression either in the absence (untreated) or presence of Silibinin with or without 
inhibitors. (B) Graphic representation of western blots showing the means + SD of n = 4 
experiments for L-NAME (red bars), Stattic (blue bars) and AKT inhibitor VIII (green 
bars) and n = 5 experiments for LY294002 (pink bars). * P < 0.05, ** P < 0.01 
significantly different to the untreated control, # P < 0.05, ## P < 0.01, ### P < 0.001 
significantly different to Silibinin alone and ns (non-significant), P > 0.05. 
 
 
Discussion 
 
93 
 
4. Discussion 
In the present study we investigated the effect of Silibinin on the cardiovascular and 
leukopoesis differentiation potential of mouse ES cells which share a variety of similarities 
with resident stem cells of many organs. After tissue injury, stem cells are activated to 
initiate and promote regenerative processes of tissue and organ repair. Previous studies had 
shown that DMSO was used as solvent for Silibinin which led to off-target effects and 
misleading results (Cavas et al., 2005). Silibinin is water insoluble which results in low 
bioavailability. We therefore used the soluble form of Silibinin, i.e. Silibinin-C-2',3-
dihydrogensuccinate, disodium salt (Legalon SIL) for the experiments of the present study. 
4.1. Effect of Silibinin on cardiomyogenesis of ES cells and Ang II-mediated cardiac 
cell function 
The pharmacologic actions of Silibinin have been mainly attributed to its hepato-protective 
and anti-cancer properties (Neha et al., 2016). However, Silibinin has also been shown to 
be pharmacologically active in the cardiovascular system. In this respect it has been 
demonstrated to exert cardioprotective properties, e.g. following isoproterenol-induced 
cardiac myocyte injury (Zhou et al., 2006; Zhou et al., 2006a) or doxorubinin-mediated 
cardiotoxicity (Raskovic et al., 2011). Moreover, Silibinin reduced blood pressure and the 
incidence of post-occlusion arrhythmias in spontaneously hypertensive rats, and it was 
suggested that this compound may be beneficial when used in hypertensive patients who 
develop acute myocardial infarction (Chen et al., 1993). Silymarin exhibited significant 
antihypertensive activity in a DOCA salt model of hypertension (Jadhav and Upasani, 
2011). In anesthetized open chest cats Silibinin lowered the amplitude and duration of 
diastolic blood pressure and produced a marked depression of cardiac contractility (Rui et 
al., 1986), suggesting that Silibinin affects the hemodynamic properties of the heart.  
The data of the present study demonstrated that Silibinin dose-dependently inhibited 
cardiomyogenesis of ES cells. Moreover, Silibinin decelerated the frequency of Ca
2+
 spikes 
in differentiated cardiac cells. To investigate whether the effects of Silibinin on 
cardiomyogenesis and cardiac cells were due to inhibition of Ang II-mediated signaling 
pathways, we investigated whether Silibinin treatment would abolish the stimulation of 
cardiomyogenesis achieved upon Ang II treatment of differentiating ES cells. In 
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corroboration with the data of Wu et al. 2013, we observed stimulation of 
cardiomyogenesis following incubation with Ang II. Moreover, Ang II treatment increased 
the contraction frequency of cardiac areas differentiated from ES cells and the frequency of 
Ca
2+
 spikes in differentiated cardiac cells. The stimulation of cardiomyogenesis as well as 
the increase in Ca
2+
 spiking frequency achieved with Ang II was completely abolished 
upon co-treatment with Silibinin, supporting the notion that Silibinin is interfering with 
Ang II signaling. Previous studies of Wu et al., 2013 and Zheng et al., 2013 suggested that 
the effects of Ang II on cardiac and smooth muscle cell differentiation were mediated via 
the AT1 receptor, since the specific AT1 receptor antagonist losartan abolished the 
observed effects. Notably, Silibinin has been discussed to act as an AT1 receptor antagonist 
in CHO cells which were stably transfected with the human AT1 receptor (Bahem et al., 
2015). We therefore investigated, whether Silibinin would abolish the Ang II-mediated 
Ca
2+
 response in smooth muscle cells which are well known to express the AT1 receptor 
(Murphy et al., 1992). Interestingly it was observed that Silibinin was not able to inhibit the 
Ca
2+
 response elicited by Ang II even at high (100µM) concentrations. Comparable data 
were obtained in DU145 prostate cancer cells which have been described to express the 
AT1 receptor (Sidorkiewicz et al., 2009) (data not shown). Thus the data of the present 
study argue against an involvement of AT1 receptor inhibition by Silibinin at least in the 
physiological Ang II concentrations (1µM) used in our experiments.  
If the AT1 receptor activity and Ca
2+
 signaling are not affected, Silibinin could 
possibly interfere with the further downstream signaling cascade. It has been previously 
described in rat neonatal cardiomyocytes, that Ang II activates ERK1/2, p38 and JNK, 
whereby the phosphorylation of p38 and JNK is dependent on reactive oxygen species 
(ROS) generation (Nishida et al., 2005). In the experiments of the present study Silibinin 
significantly inhibited ERK1/2, p38 and JNK activity as compared to the untreated control, 
whereas MAPK stimulation was observed upon Ang II treatment. According to our 
assumptions Silibinin totally abolished the stimulation of all members of the MAPK family 
by Ang II, which indicates that the compound interferes with the MAPK signaling cascade 
downstream of the AT1 receptor. Since NO is well known as a free radical scavenger for 
ROS (Kumar et al., 2017), it may be assumed that the inhibitory effect of Silibinin on 
MAPK activity may be due to its capacity to raise NO concentration in the tissue. Previous 
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data from others who showed that Silibinin protects H9c2 cardiac cells from oxidative 
stress and inhibits phenylephrine-induced hypertrophy, presumably by repression of the 
phenylephrine-induced phosphorylation of ERK1/2 kinases (Anestopoulos et al., 2013), are 
pointing to the same direction. Moreover, the property of Silibinin to act as a free radical 
scavenger has been validated in several studies (Mira et al., 1994; Dehmlow et al., 1996a; 
Ali et al., 2018). 
The RAAS has been shown to exert deep impact on cardiac development (Price et 
al., 1997). In humans all components of RAAS are expressed at very early stages of 
embryogenesis (30-35 days of gestation) in different organs, suggesting that Ang II likely 
plays a role in the growth and differentiation of various organotypic cells (Schutz et al., 
1996). Although triple knockouts of the AT1a, AT1b and AT2 receptors are viable and 
fertile, the lack of both AT1 receptor subtypes was associated with atrophic changes in the 
myocardium, a reduced coronary flow and a reduced left ventricular systolic pressure 
(Gembardt et al., 2008; van et al., 2010). Recently it has been outlined, that anti-
hypertensive medication of pregnant women is associated with increased risk for congential 
heart defects. This was the case for the treatment with ß-blockers as well as with the use of 
RAAS blockers (Fisher et al., 2017). Milk thistle seeds as well as their pharmacologically 
active ingredients are frequently used as dietary herbal supplements mainly to detoxify the 
liver. Since the data of the present study demonstrate that Silibinin inhibits cardiac 
differentiation of ES cells and affects Ang II-mediated signaling cascades, its use should be 
avoided in pregnant women.  
 
4.2. Silibinin and Ang II effects on rat adult cardiac cell function 
Ang II exerts vasoconstrictor effects and RAAS blockers are used in humans as blood 
pressure lowering agents. In addition Ang II has been shown to induce cardiac hypertrophy 
by acting directly on the heart tissue as well as indirectly through hypertension and 
increased hemodynamic forces within the heart (Steckelings et al., 2007; Danser, 2010; Xu 
et al., 2010; Zhou et al., 2016). To explain the effect of Silibinin and Ang II on cardiac cell 
function, adult rat cardiomyocytes were treated overnight with Ang II (10μM) in presence 
or absence of Silibinin (20μM) and cell shortening, relaxation velocity, diastolic cell length 
(L diastolic) and R50-TTP 50 (time to reach 50% relaxation- time-to-peak 50% (TTP 50)) 
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were investigated as previously described (Mufti et al., 2008). As previously demonstrated 
by Mufti et al. (2008) Ang II treatment significantly reduced cell shortening, decreased 
relaxation velocity, diastolic cell length and the time to reach 50% relaxation compared to 
untreated controls. The observed inhibition of cardiac cell function achieved with Ang II 
was completely reversed by Silibinin treatment. The adverse effect of Ang II on cardiac cell 
function may be due to the increase in cellular oxidative stress which occurs upon AT1 
receptor binding by Ang II. Since Silibinin has been demonstrated to exert anti-oxidative 
properties in several studies (Lu et al., 2009), the preservation of cardiac cell function in the 
presence of Silibinin may be due to its radical scavenging properties. Increased Ang II 
levels play a pivotal role in adverse myocardial remodeling and progression to heart failure 
which are currently treated by ACE inhibitors or AT1 receptor blockers (Patel et al., 2016). 
Due to its low toxicity and good tolerance Silibinin may be used in future to prevent Ang 
II-mediated cardiac remodeling and heart failure progression.  
 
4.3. Stimulation of vasculogenesis by Silibinin 
Our data demonstrated that very low concentrations (1-10µM) of Silibinin exerted a pro-
angiogenic effect associated with increased branching points, VE-cadherin, VEGFR2 and 
HIF-1α protein expression, whereas higher concentrations of Silibinin (up to 50µM) were 
anti-angiogenic, however without increasing overall toxicity of this compound (data not 
shown). The dose-dependent pro- and anti-angiogenic activity may explain the conflicting 
data of previous studies which demonstrated anti-angiogenic effects at Silibinin 
concentrations of approximately 100µM (Lin et al., 2013), whereas protective effects on 
endothelial cells were observed at concentrations below 100µM (Wang et al., 2005).  
To unravel the pro-angiogenic effect of Silibinin, we assessed NO generation and 
eNOS activation since NO is well known to exert pro-angiogenic effects in vitro and in vivo 
(Ghimire et al., 2017). Indeed Silibinin treatment dose-dependent increased NO generation 
with maximum effects at 10µM and adverse effects at higher concentrations. Moreover, 
activation of eNOS was observed within 30 min of Silibinin treatment. The anti-oxidative 
activity of Silibinin has been described in numerous studies, and has been attributed to 
direct radical scavenging, chelation of iron and copper, inhibition of ROS producing 
enzymes and activation of anti-oxidant enzymes (Surai, 2015). The potential role of NO as 
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a mediator of Silibinin´s anti-oxidative activity has so far not sufficiently been investigated, 
although it has been previously shown that very high concentrations of Silibinin (400µM) 
exerted nitrosative stress in human epidermoid carcinoma A431 cells (Yu et al., 2012) and 
HeLa cells (Fan et al., 2011). Notably, it has been discussed, that there exists an inter-
regulation pattern between reactive nitrogen species (RNS) and ROS generation upon 
Silibinin treatment of cultured cells (Wang et al., 2010) which may be involved in the cyto-
protective versus cyto-toxic effect of this compound. In this respect it has to be kept in 
mind that the same chemical compound can act as a pro-oxidant as well as anti-oxidant, 
which is dependent on the overall oxidative milieu in the cell or tissue as well as the 
concentration of the investigated agent. Therefore, the data of the present study suggest that 
higher (> 20µM) concentrations of Silibinin may raise ROS towards levels which inhibit 
eNOS phosphorylation, NO generation and vascular differentiation from ES cells. 
To investigate the signaling pathways involved in the generation of NO and 
stimulation of vasculogenesis of ES cells, we assessed activation of PI3K, STAT3 and 
AKT and determined whether pharmacological inhibition of these protein kinases would 
interfere with NO generation as well as vascular structure formation upon treatment with 
Silibinin. The PI3K/AKT pathway has been previously shown to be essential for several 
key endothelial cell (EC) functions, including cell growth, migration, survival, and vascular 
tone (Lee et al., 2014), and has been demonstrated in various studies to activate eNOS in 
the downstream signaling cascade (Lee et al., 2006; Erdogdu et al., 2010; Yu et al., 2011). 
STAT3 is required for both basal and growth signal-induced expression of HIF-1α (Hooper 
et al., 2007) and regulates VEGF expression (Niu et al., 2002). Presumably STAT3 
regulates VEGF activation by directly interacting with the binding site on 5' region of 
VEGF gene (Lv et al., 2017). Recently it has been shown that the RNA-binding protein 
Quaking isoform 5 (QKI-5) is an important regulator of STAT3 stabilization and VEGFR2 
activation during the endothelial cell differentiation process of induced pluripotent stem 
(iPS) cells (Cochrane et al., 2017). 
In the present study it was shown that Silibinin treatment of EBs activated PI3K, 
STAT3 and AKT. Inhibition of PI3K abolished activation of STAT3, AKT as well as NO 
generation and vascular structure formation. Comparable results were achieved upon 
inhibition of STAT3 and AKT, which clearly demonstrates that Silibinin is activating the 
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PI3K/AKT/STAT3/eNOS pathway to stimulate vasculogenesis of ES cells (figure 4.1). 
Since NO generation and eNOS phosphorylation upon Silibinin treatment was inhibited 
upon pharmacological intervention with the PI3K/AKT/STAT3 pathway, it can be 
concluded, that the action of Silibinin is not just related to its anti-oxidative capacity, but to 
specific activation of signaling pathways known to be related with NO generation and 
blood vessel formation. 
 
4.4. Enhancement of leukopoiesis upon Silibinin treatment 
Silibinin has been shown to exert organ-protective and regenerative properties which may 
be related to its reported anti-inflammatory action (Choi et al., 2012; Guo et al., 2016; Kim 
et al., 2016). Moreover, Silibinin may have impact on immune function in a complex way. 
Since regenerative processes involve stem cells, we investigated whether Silibinin would 
affect the differentiation of CD45
+
, CD18
+
 and CD68
+
 cells which are indicative for the 
monocyte/macrophage cell lineage. Our data demonstrated that indeed Silibinin dose-
dependent increased the differentiation of cells which were positive for leukocyte markers, 
with maximum effects achieved at 10µM Silibinin, whereas higher concentrations exerted 
adverse effects. The strict concentration dependence of this compound´s biological action 
may be one of the explanations for the conflicting data existing on the anti-oxidative and 
anti-inflammatory properties of Silibinin and the activation versus inhibition of specific 
signaling pathways (Verma and Thuluvath, 2007). In this respect it has been shown that 
Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory 
processes at high doses (Johnson et al., 2003). It is well known that one and the same 
substance can act as a pro-oxidant or anti-oxidant, depending on the concentration, the 
cellular context, the balance between ROS and RNS and the presence of catalyzing metals 
like Cu and Fe which promote the pro-oxidant activity of natural anti-oxidants (Pisoschi 
and Pop 2015; Adegbola et al., 2017). To assess the signaling pathways underlying the 
differentiation of cells expressing leukocyte markers, we investigated the activation of 
STAT3 which is a central component of the JAK/STAT signaling cascade. STAT3 is an 
important transcription factor required for growth and differentiation of hematopoietic stem 
cells (Hillmer et al., 2016). STAT3 deficiency renders hematopoietic progenitor cells and 
myeloid precursors refractory to the growth-promoting functions of G-CSF (Zhang et al., 
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2010). Interestingly, STAT3 has been recently attributed anti-inflammatory activity in 
haematopoiesis (Martelli et al., 2010), which may contribute to the inflammation lowering 
capacity, which has been reported for Silibinin in different experimental settings. 
Moreover, activation of PI3K and AKT, which are involved in central pathways directing 
cardiovascular differentiation of ES cells (Bekhite et al., 2011), was investigated. Notably, 
the PI3K/AKT/mTOR signaling network regulates proliferation, survival, and 
differentiation events during haematopoiesis (Martelli et al., 2010), whereby a signaling 
pathway consisting of PI3K/AKT-NF-κB-Bcl-xL regulates survival of macrophages during 
and after differentiation from monocytes (Busca et al., 2014). Our data demonstrate that 
treatment with Silibinin (10µM) activated STAT3 as well as PI3K and AKT within few 
minutes of incubation, which may indicate that this compound is directly activating growth 
factor/cytokine receptors, thereby initiating specific signaling pathways. This assumption 
would implicate, that the anti-inflammatory action of Silibinin is not just due to the radical 
scavenging chemical structure of this flavonolignan, but to the initiation of receptor 
regulated anti-inflammatory signaling cascades, which indirectly results in anti-oxidative 
action. Our previous observations, that Silibinin activates NO generation by eNOS 
stimulation, which was inhibited upon interference with STAT3 and PI3K/AKT (Ali et al., 
2018) (figure 4.1), and the observation, that Silibinin raised NO in CD68
+
 cells (data not 
shown), point in this direction. To underscore the notion that Silibinin is stimulating the 
differentiation of cells expressing leukocyte markers through STAT3 and PI3K/AKT 
signaling pathways, we applied pharmacological inhibitors. Notably, inhibition of STAT3 
by Stattic, PI3K by LY294002 and AKT by AKT inhibitor VIII totally abolished 
expression of CD45, CD18 and CD68 achieved upon treatment of differentiating ES cells 
with Silibinin. Moreover, the applied inhibitors blunted the stimulation of VEGFR2 and 
HIF-1α expression, which was observed upon Silibinin treatment of differentiating ES 
cells. In our recent study we demonstrated that Silibinin-stimulated vasculogenesis from ES 
cells, which is well known to be regulated by VEGFR2 and HIF-1α-mediated signaling 
pathways (Ali et al., 2018). Vasculogenesis and haematopoiesis are two closely related 
events, which are regulated by the gene cloche, a master regulator of the endothelial and 
haematopoietic cell fate (Reischauer et al., 2016). Previous studies of us demonstrated that 
inhibition of VEGFR2 receptors abolished not only vasculogenesis, but also leukopoiesis 
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(Hannig et al., 2010). Whereas vasculogenesis in mouse ES cells occurs within the first 9 
days following removal of LIF from the cell culture medium, the differentiation of 
leukocytes occurs between day 12 and day 14 of cell culture, which implies that inhibition 
of vasculogenesis should abolish differentiation of leukocytic cells (Hannig et al., 2010). 
During embryogenesis haematopoietic stem cells differentiate from a population of 
endothelial cells called haemogenic endothelium (HE) in a process called the endothelial-
to-haematopoietic transition (EHT) and is regulated by the transcription factor Runx1 
(Yzaguirre et al., 2018). Recently transcriptional overlap between haemogenic endothelial 
cells and haematopoietic progenitor cells was reported (Angelos et al., 2018). Moreover, it 
was reported that HIF-1α and HIF-2α regulate haemogenic endothelium and hematopoietic 
stem cell formation in zebrafish (Gerri et al., 2018). 
 The most important biological activity of Silibinin is its liver-protective effect 
(Wellington and Jarvis, 2001), which may be associated to the initiation of regenerative 
processes. Recent studies have shown that in a murine model of hepatic injury and fibrosis, 
treatment with bone marrow derived macrophages (Thomas et al., 2011) or macrophages 
differentiated from ES cells (Haideri et al., 2017) can improve liver regeneration and 
reduce fibrosis. Since the data of the present study demonstrate that leukocytic 
differentiation occurs from ES cells upon Silibinin treatment, it may be speculated that 
differentiation of resident stem cells in the liver towards cells of the monocyte/macrophage 
lineage may be an important corner mark in the regenerative properties of this milk thistle 
ingredient.  
 
 
 
 
 
 
 
 
 
 
Discussion 
 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Schematic representation of Silibinin action in differentiating mouse ES 
cells. Silibinin downregulates cardiomyogenesis of ES cells presumably by inhibition of 
ERK1/2, p38 and JNK downstream of the AT1 receptor. On the other side Silibinin 
stimulates vasculogenesis and leukopoiesis by activating the PI3K/AKT/STAT3/eNOS 
signaling pathway and up-regulation of NO generation. 
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5. Summary 
In the current study the effect of Silibinin-C-2’, 3-bis (hydrogensuccinate), Disodium salt 
on cardiovascular differentiation and leukopoiesis of mouse ES cells was investigated. 
Silibinin is a bioactive substance from milk thistle (Silybum marianum (L.) Gaertn.), and 
owns cell and organ regeneration-promoting properties. 
It was demonstrated that Silibinin-stimulated vasculogenesis, the expression of 
vasculogenic proteins (VEGFR2, HIF-1α, VE-Cadherin) and leukopoiesis (CD45+-, 
CD18
+
-, and CD68
+ 
-cells) of ES cells, whereas an inhibition of cardiomyogenesis was 
observed. 
Silibinin inhibited the Ang II-mediated stimulation of cardiomyogenesis of ES cells as well 
as the Ang II-mediated increase in contraction frequency and frequency of Ca
2+
 spikes. 
However, not by blockage of the AT1 receptor itself, but by inhibition of ERK1/2, p38 and 
JNK signaling pathways downstream of the AT1 receptor. In adult rat cardiomyocytes 
Silibinin reversed the inhibition of cell contractility following Ang II treatment. 
Treatment of differentiating ES cells with Silibinin resulted in NO generation and 
activation of eNOS within few minutes. Furthermore, activation of the PI3K/AKT and 
STAT3 signaling pathway was observed. Inhibition of NO generation by L-NAME, STAT3 
activation by Stattic, AKT activation by AKT inhibitor VIII and PI3K activation by 
LY294002 abolished the stimulation of vasculogenesis and leukopoiesis by Silibinin. 
Stattic inhibited the Silibinin-induced eNOS and AKT activation as well as NO generation. 
AKT inhibitor VIII inhibited the Silibinin-mediated NO generation and eNOS as well as 
STAT3 phosphorylation. The PI3K inhibitor LY294002 blunted Silibinin-mediated NO 
generation, eNOS activation as well as AKT and STAT3 phosphorylation. 
In conclusion the data of the present study show that Silibinin stimulates vasculogenesis 
and leukopoiesis of ES cells through a NO-mediated and PI3K/AKT- as well as STAT3-
regulated signaling pathway. On the other hand Silibinin prevents cardiomyogenesis 
through inhibition of the Ang II signaling pathway on the level of the ERK1/2, p38 and 
JNK signaling cascade. 
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6. Summary (German)  
Zusammenfassung 
In der vorliegenden Studie wurde der Effekt von Silibinin-C-2’, 3-bis (Hydrogensuccinat), 
Dinatriumsalz auf die kardiovaskuläre Differenzierung und Leukopoiese von ES Zellen der 
Maus untersucht. Silibinin ist eine in der Milchdistel (Silybum marianum (L.) Gaertn.) 
vorkommende bioaktive Substanz mit Zell- und Organ-Regenerations-fördernden 
Eigenschaften. 
 
Es konnte gezeigt werden, dass Silibinin die Vaskulogenese, die Expression vaskulogener 
Proteine (VEGFR2, HIF-1α, VE-Cadherin) und Leukopoiese von ES Zellen (CD45+-, 
CD18
+
-, CD68
+
-Zellen) förderte, wogegen eine Inhibition der Kardiomyogenese 
beobachtet wurde. 
 
Silibinin inhibierte die Ang II-vermittelte Stimulation der Kardiomyogenese von ES Zellen 
und die Ang II-induzierte Steigerung der Kontraktionsfrequenz und der Frequenz von Ca
2+
 
Transienten, jedoch nicht durch Blockierung des AT1 Rezeptors, sondern durch Hemmung 
der ERK1/2, p38 und JNK Signalwege, die dem AT1 Rezeptor nachgeschaltet sind. In 
adulten Kardiomyozyten der Ratte revertierte Silibinin die durch Ang II inhibierte 
Zellkontraktilität. 
 
Nach Behandlung differenzierender ES Zellen mit Silibinin konnte im Verlauf weniger 
Minuten eine Generierung von NO durch Aktivierung der eNOS festgestellt werden. 
Weiterhin wurde eine Aktivierung des PI3K/AKT und STAT3 Signalweges beobachtet. 
Eine Inhibition der NO Generierung durch L-NAME, der STAT3 Aktivierung durch 
Stattic, der AKT Aktivierung durch AKT Inhibitor VIII und der PI3K Aktivierung durch 
LY294002 verhinderte die Stimulation der Vaskulogenese und Leukopoiese durch 
Silibinin.  
 
Stattic inhibierte die Silibinin-vermittelte eNOS und AKT Aktivierung sowie die NO-
Generierung. Der AKT Inhibitor VIII inhibierte die Silibinin-induzierte NO Generierung 
sowie die eNOS und STAT3 Phosphorylierung. Der PI3Kinase Inhibitor LY294002 
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inhibierte die Silibinin-induzierte NO Generierung, eNOS Aktivierung und die AKT und 
STAT3 Phosphorylierung. 
 
Die Daten der vorliegenden Studie zeigen somit, dass Silibinin die Vaskulogenese und 
Leukopoiese von ES Zellen über einen NO-vermittelten und PI3K/AKT und STAT3 
regulierten Signalweg induziert. Auf der anderen Seite verhindert Silibinin die 
Kardiomyogenese durch Inhibition des Ang II Signalwegs auf der Ebene des ERK1/2, p38 
und JNK Signalwegs. 
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7. List of abbreviations 
 
α- and β-MHC  α- and β-myosin heavy chain  
ºC Degree Celcius 
3D  Three-dimensional 
ACE An angiotensin-converting-enzyme 
AKT Protein kinase B 
AKT inh. VIII AKT inhibitor VIII 
Ang II Angiotensin II 
AT1 Angiotensin II receptor 1 
AT2 Angiotensin II receptor 2 
BMP Bone morphogenetic protein 
Ca
2+
  Calcium  
CD31 Cluster of differentiation 31 
CHO Chinese hamster ovary  
Cu Copper 
Cu2SO4 Copper Sulfate 
DAF-FM  4-amino-5-methylamino-2',7'-difluorofluorescein diacetate  
DMEM  Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DOCA Deoxycorticosterone acetate  
DRAQ5 1, 5-bis{[2-(di-methylamino)ethyl]amino}-4, 8-
dihydroxyanthracene-9, 10-Dione 
EBs Embryoid bodeis 
EC Endothelial cell  
E-C Excitation-contraction 
EC Cells Embryonic carcinoma Cells 
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